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ABSTRACT 
The effects of chronic treatment with thyroxine, pargyline , and com~ 
bined thyroxine and pargyline were simultaneously determined on locomotor 
activity, systolic blood pressure, urinary sodium and potassium excretion, 
body weight gains and terminal monoamine oxidase activity in brain and 
liver of male albino rats . 
Chronic locomotor exploratory activity was shown to be best measured 
by comparing only the first 30-minute counts of groups of rats run on alter-
nate days in the actophotometer. Significant (PS 0.05) depression of 
exploratory activity occurred during 11 days of daily intraperitoneal in-
jection of thyroxine, pargyline or both these drugs concurrently. Rats 
receiving thyroxine or both thyroxine and pargyline lost weight beginning on 
day 2 or 1, respectively, but rats receiving pargyline alone lost no weight. 
Treatment with thyroxine elicited continuous hypertension and apparently in-
creased heart rate and stroke volume ; these first appeared on day 2 and were 
present 17 treatment days later. After 4 days of treatment with both drugs 
there was no hypertension, but heart rate and stroke volume appeared in-
creased. Treatment with pargyline alone appeared to reduce these latter 
effects, and induced continuous hypotension beginning between days 2 and 7. 
Urinary excretion of sodium and potassium was continually increased 
after 7 days of treatment with thyroxine, but not with pargyline or with 
both drugs . TermLnal monoamine oxidase activity in brain and liver was not 
affected by thyroxine treatment but was completely suppressed in rats receiv-
ing pargyline or both drugs . 
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I. INTRODUCTION 
In 1961 Kline reported that concurrent administration of thyroid 
extract and monoamine oxidase inhibitors to psychotic patients resulted in 
increased depression and apathy. Kline felt that this response was para-
doxical since he had observed a measure of reduction in psychotic depression 
after administration of either thyroid alone or a monoamine oxidase inhibi-
tor alone. 
It was decided to examine this problem in the laboratory using normal 
rats. Thyroxine and pargyline were selected as representative of thyroid 
hormones and the monoamine oxidase inhibitors, respectively, and a method 
was developed that permitted the efficient measuring of locomotor activity 
in rats. A study was then designed in which a simultaneous evaluation could 
be made of the effects, in rats, of chronic treatment with thyroxine, pargy-
line or both thyroxine and pargyline on locomotor activity, systolic blood 
pressure, body weight gains, urinary sodium and potassium excretion and ter-
minal monoamine oxidase activity in brain and liver. It was felt that any 
drug-induced changes in locomotor activity might parallel changes induced by 
the drugs in the other parameters being considered. These parameters were 
chosen because they were perhaps the most likely to be affected by thyroxine 
and pargyline, and the whole study was developed in order to obtain a corre-
lated profile of the effects of these drugs on the parameters studied. 
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II. SURVEY OF TIIE LITERATURE 
On Christmas Day 1914, E. C. Kendall isolated fran an iodine-
containing protein fraction of the thyroid gland a physiologically active 
crystalline product which he called "thyroxin" (Trotter, 1964). Half a 
century of subsequent research has specified many effects of thyroid hor-
mones in the body, but Wolff and Wolff (1964) have stated flatly that the 
mechanism of action of these hormones is still unknown. 
From the discussion of Morgans (1964) the pertinent metabolic and 
clinical phenomena observed in hyperthyroidism can be summarized as follows: 
1. Increased caloric production. 
2. Increased plasma volume and increased rate of water 
filtration through capillary walls. 
3. Increased cardiac output and decreased circulation 
time. 
4. Increased heart rate. 
5. Increased renal blood flow and glomerular filtration 
rate. 
6. Loss of weight and increased appetite. 
7. Excessive thirst. 
8. Increased nervouEness, irritability and tremors. 
9. Excessive sweating and heat intolerance. 
A. The Hemodynamic Effects of Thyroid Hormone 
Barker~ !.!,.(1965) showed that thyroxine and many structural ana-
logs increased the heart rate in rats. Bray (1964) demonstrated that 
tri-iodothyronine (T-3) administered subcutaneously (s.q.) to rats every 
other day for a week and then daily for a second week also significantly 
increased the heart rate. He showed that the tachycardia was accompanied 
8 
9 
by an increased sensitivity to catecholamines and was abolished by reser-
pine or guanethidine. He suggested that the tachycardia of the hyper-
thyroid state is due to adrenergic stimulation. Wurt man et al . (1964) 
--
showed in addition that the epinephrine-induced increase in cardiac output 
was potentiated in hyperthyroidism. The mean blood pressure of the hyper-
thyroid rats in this study did not, however, appear to be significantly 
elevated over the controls. On the other hand Zsoter et aL ( 1964) showed 
--
that daily oral administration of I-thyroxine, thyroid powder or T-3 for 
2 weeks did significantly increase systolic blood pressure in dogs and cats. 
Danowski!:,! !,!.(1964) reported similar findings in healthy adult volunteers: 
large doses of desiccated thyroid induced thyrotoxicosis accompanied by 
increased sensitivity to injected epinephrine. Danowski also measured the 
pressor response of i~inea pig aortic strips to the serum and urine col-
lected during these studies. It was found that the tachycardia a~d increases 
in systolic blood pressure induced by thyroid excesses were accompanied by 
increases in the aortic-strip pressor activity of urine but not of serum . 
Exogenous epinephrine produced a greater rise in systolic blood pressure 
and tachycardia in the hyperthyroid state, but these responses we r e not 
accompanied by increased titers of pressor activity in serum. It was pos-
tulated, then, that the excess thyroid hormone was potentiating the effect 
of exogenous epinephrine in the heart. A peripheral effect was ruled out 
because epinephrine in the doses used in this study produced increased car-~ 
diac output and systolic pressure, accompanied by net peripheral vasodilat ion 
with decreased diastolic pressure. Danowski referred to the work of Wurtman 
~ !.!· ( 1964) who showed that "in thyrotoxicosis the heart receives the same 
fraction of circulating labeled epinephrinr per gram of cardiac tissue but 
its capacity to inactivate the epinephrine by binding is dimin i shed. On 
the basis of these findings it was suggested that the consequent mainten-
ance of elevated levels of free epinephrine in the heart during hyper-
thyroidism may be a major factor in the enhanced hemodynamic responses to 
epinephrine." 
Thus it appears likely that the hemodynamic responses to thyroid 
hormones are closely related to levels of epinephrine in the heart and 
probably not to peripheral effects of epinephrine. 
B. ~ Hemodynamic Effects of Pargyline Hydrochloride 
1 Pargyline hydrochloride (Eutonyl , MO 911), (N-benzyl-N-methyl-2-
10 
propynylamine hydrochloride) is a potent, irreversible nonhydrazine monoamine 
oxidase (MAO) inhibitor with striking ability to effect reductions in 
elevated blood pressure. In preliminary studies Maronde ~ !.!.(1963) re-
ported that pargyline produced a significant drop in the standing blood 
pressure of 29 hypertensive patients, but showed little effect on pressures 
of supine patients. Horwitz and Sjoerdsma (1963) found that pargyline pro-
duced orthostatic hypotension and was effective in reducing a case of hyper-
tension that could not be controlled even after administration of 
guanethidine ·in doses of 450 mg daily. In addition, they found that pargyline 
elevated mood and showed no parasympatholytic properties. 
The findings of Brest~ !-.4(1963) agreed with those of Maronde ~ !.!· 
(1963) that pargyline had less effect in the supine position than in the 
erect position. Brest~ al.attributed the overall reduction in blood pres-
sure primarily to a reduction in peripheral vascular resistance. They noted 
that in most of the cases studied pargyline elicited no consistent change in 
pulse rate or cardiac output but did decrease total peripheral resistance in 
all cases. They also reported that because renal vascular resistance was 
1. Registered Trademark, Abbott Laboratories, Chicago, Illinois. 
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similarly reduced, renal blood flow and glomerular filtration rate are 
affected only to a moderate extent. 
The sites and mechanisms of action of pargyline in lowering blood 
pressure have been the subjects of much controversy. Wolf!,!.!!.· (1963) 
ruled out adrenergic blockade and depression of central sympathetic centers 
as being of any major importance and suggested that MAO inhibitors decrease 
blood pressure by sympathetic ganglionic blockade. This mechanism is 
probably not a likely one, however. Horwitz and Sjoerdsma (1963) had noted 
that pargyline produced no parasympatholytic effects, implying perhaps that 
there was no blockade of autonomic ganglia. More recently Winsor (1964) 
stated categories lly: "Pargyline hydrochloride does not behave like a 
i. ganglionic blocking agent." He ' noted that although the antihypertensive 
effects are primarily orthostatic and that occasional reports of parasympa-
tholytic side-effects such as dryness of mouth and constipation are seen, 
"there is no clear-cut clinical evidence to justify its classification as a 
ganglionic blocker". His data showed that although in pargyline therapy 
the antihypertensive effect was not always accompanied by increased urinary 
excretion of tryptamine, it was always accompanied by an abolishment of the 
digital reflex. This latter phenomenon indicates a pargyline-induced reduc-
tion in peripheral resistance. 
Thus it appears likely from these data and from the work of Brest et al. 
(1963) that pargyline exerts its antihypertensive effect primarily by de-
creasing peripheral resistance. Winsor suggested a blockade of postganglionic 
sympathetic fibers as a possible mechanism. Although this appears likely 
since other sites in the autonomic nervous system have been ruled out, it 
obviously tells us little about a specific site of action. Indeed, Winsor 
made it clear that his work failed to show any consistent positive correlatioq 
between MAO inhibition as reflected in the increased urinary excretion of 
tryptamine, and the antihypertensive effects of pargyline as mediated by 
reduced sympathetic activity. 
12 
In searching for an explanation of the hypotensive effects of MAO in-
hibitors, Goldberg (1964) also agreed that pargyline-induced orthostatic 
hypotension appears to be produced by decreased peripheral resistance 
mediated by peripheral depression of sympathetic activity. He points out 
that since the action of injected norepinephrine is not blocked in conditions 
of MAO inhibition it is certain that the MAO inhibitors are not adrenergic 
blockers. But he emphasizes that evidence for the postulated blocking 
effect of these drugs on postganglionic release of norepinephrine is not 
unequivocal. Presser agents such as tyramine that act indirectly by releas-
ing bound norepinephrine act with greater effect in MAO-inhibited animals 
than in normal animals. Goldberg suggests that this happens because the 
usual continuous destruction of norepinephrine by MAO in nerve endings is 
blocked; consequently, bound norepinephrine accumulates, and the relatively 
larger amounts subsequently released by agents such as tyramine cause greater 
presser response. But the presser response of injected norepinephrine is not 
potentiated in MAO-inhibited animals. Goldberg suggests that catechol-0-
methyl transferase (CCMT) in the liver inactivates injected norepinephrine so 
that exaggerated responses are not seen. But the increased levels of en-
dogenous norepinephrine bound in nerve endings as a result of MAO inhibition 
are released by agents such as tyramine and amphetamine directly onto the 
receptor sites and consequently an exaggerated presser response is seen with 
these drugs. 
It is clear from the foregoing that the hypotensive effects of MAO 
inhibitors are probably caused by peripheral sympathetic blockade at some 
13 
site in the postganglionic apparatus rather than by central effects or by 
peripheral adrenergic blockade. The specific role of MAO inhibition in this 
sympathetic blockade has not been clarified, but recent work by Kopin~.!!· 
(1964, 1965) forms the basis for a new approach to this question. 
Kopin~ !!..(1964) reported that increased tissue and urinary levels 
of amines were seen after MAO inhibition. In the rabbit, elP.vated tissue 
levels of octopamine, a relatively inactive amine (the beta-hydroxylated 
derivative of tyramine) were observed after MAO inhibition, and it was shown 
that chronic treatment with MAO inhibitors resulted in diminished release of 
norepinephrine from the isolated, perfused cat spleen upon stimulation of 
its sympathetic nerve supply. From these and other data it appeared likely, 
then, that an impaired release of norepinephrine from sympathetic nerve 
endings resulted from an accumulation of amines in th~ tissues following 
treatment with MAO inhibitors. 
Wh MAO · · h·~· d · t' · c14 en is in 1u1te , tyram1ne excre ion increases; moreover, -
tyramine is rapidly converted to c14-octopamine and selectively retained in 
the tissues after all the tyramine is destroyed. Since very little octo-
pamine is formed after sympathectomy it is likely that these processes occur 
in the sympathetic nerves. It was the object of Kopin~ .!!·(1964), there-
fore, to determine whether octopamine accumulates in the sympathetic nerves 
after inhibition of MAO, and whether this amine can be released as a "false 
neurochemica 1 transmitter": that is, "a substance normally not present in 
significant amounts in the sympathetic nerves, which can be made to accumu-
late in the nerve endings and which can then be discharged by sympathetic 
nerve stimulation". 
The following results were reported in this study: 
1. After 2 days of treatment with pheniprazine, an inhibitor of MAO, 
octopamine levels in the cat salivary glands were greatly increased. This 
effect was not seen if the gland was sympathetically denervated. 
2. d · · t · f c14 t · c
14 t · f d · After a m1n1s ration o - yramine, -oc opamine was oun in 
much higher concentrat i ons in intact salivary glands than in denervated 
glands. When the cats were first given pheniprazine there was no increase 
in c14-octopamine levels in denervated glands, but a tenfold increase was 
found in intact glands. 
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3. Isolated, perfused spleens from untreated cats were infused with 
c14-tyramine; 30 minutes later the sympathetic nerves were stimulated and 
there resulted a marked increased in the rate of appearance of c14-octopamine 
in the effluent. After administration of epinephrine the spleen contracted 
as it did on nerve stimulation, but no increase in c14-octopamine release 
was seen. 
From these data Kopin!:..!,!!. formulated the following hypothesis: 
Following inhibition of monoamine oxidase, endogenously 
formed amines, such as tyramine, usually destroyed by 
this enzyme, are taken up by these vesicles and converted 
to the beta-hydroxylated derivatives. These beta-
hydroxylated amines take the place of a portion of the 
norepinephrine normally contained in the vesicles and 
are re leased with the catecholamine. If each impulse 
releases a limited number of transmitter molecules, less 
norepinephrine would be released, a portion being replaced 
by less active molecules, even if tissue levels of norepine-
phrine are elevated. This would result in apparent 
sympathetic blockade, especially at low rates of nerve 
stimulation. At high, unphysiological rates of nerve 
stimulation, a sufficient number of vesicles could be made 
to release their contents so that the apparent block would 
be overcome. 
Thus the most current views of the mechanism whereby MAO inhibitors 
effect a sympathetic blockade, resulting in decreased blood pressure, rest 
on the concept of the formation and release of a false neurochemical trans-
mitter. 
C. Thyroxine, Pargyline ~Urinary Sodium~ Potassium 
Gaunt and Birnie (1951) reported that administration of thyroid 
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hormones to hypothyroid patients resulted in diures i s and increased sodium 
(salt) excretion. Euthyroi d subje cts , however , showed increased potassium 
excretion after thyroid administration. In t yrotoxicosi s there is an in-
creased urinary excretion of both sodium and potassium, and increased amounts 
of urinary nitrogen, phosphorus, calc ium, chloride and creatine are also seen 
(Williams and Bakke , 1962). 
Ganog (1963) suggested that the increased urinary excretion of potas-
sium was due to the protein catabolism accompanying hyperthyroidism. If 
food intake is not increased, catabolism of body protein and fat stores occurs; 
weight is lost and urinary nitrogen levels increase. The latter is an index 
of amino acid degradation and hence of protein degradation. It is probable 
that the excess potassium is of intracellular origin. As protein is degraded 
the integrity of body cells is lost, and the potassium normally kept inside 
the intact cells by a process of active transport is liberated and lost into 
the urine. 
It is somewhat difficult to reconcile the increased urinary sodium 
and potassium seen in hyperthyroidism with the findings of two recent studies 
concerning the effects of thyroid on serum constituents. Although adminis-
tration of desiccated thyroid to healthy adult prisoners did re sult in in-
creases in serum potassium levels one week after institution of daily therapy, 
the serum sodium was decreased (Moses ~ .!!.·, 1964). The investigators indi-
cated that these alterations had not previously been recognized, and 
speculated that the hyponatremic effect might reflect a lowering of intra-
cellular solutes as a result of tissue wasting. On the other hand Liu and 
Overman (1964) found no change in serum sodium and potassium levels in rats 
after administering toxic doses of thyroxine (1.4-2.0 mg Na thyroxine/kg) 
daily for 25 days. Some difficulty remains, then, in understanding how tissue 
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potassium presumably re leased in hyperthyroidism and appearing in the urine 
is nevertheless not always reflected in increased serum levels. 
Following a clinical trial of pargyline hydrochloride in 25 out-
patients Sutnick ~ .!,!. (1964) reported that no significant changes in 
urinary or blood constituents had occurred. The glomerular filtration rate 
is moderately reduced in pargyline therapy (Brest!,! al., 1964; Onesti !,! .!.!·, 
1964), but apparently no changes in urinary or blood electrolytes have been 
noted. Progressive renal failure is an indication that pargyline therapy 
should be stopped (Abbott Laboratories, 1964). 
D. Thyroxine, Pargyline !!!,2 Behavior 
The behavioral effects observed in hyperthyroidism have been known 
for many years. Clinical observations noted below have been summarized froo 
the discussion of Williams and Ba~ke (1962). 
Muscle weakness and fatigue are very common in hyperthyroidism. 
Skeletal muscle apparently degenerates in some cases; generally, muscle 
weakness may be accounted for by the reduced capacity of the body to phos-
phorylate creatine and by reduced levels of nutrients. These observations 
are, of course, the manifestations of thyroid action at the subcellular level . 
An enormous amount of work has been done in an attempt to explain the in-
creased oxygen consumption and the generally depressed P:O ratios seen as a 
result of thyroxine administration or in vitro action. It is not possible 
here to discuss this work. Wolff and Wolff (1964) stated that depending on 
the dosage, the particular hormone used and the experimental conditions, un-
coupling of oxidative phosphoryla tion, " : oosened coupling" or even stimula-
tion of oxidative phosphorylation have been reported, 
The effects of thyroid hormones on the nervous system are unexplained, 
but symptoms almost always include nervousness, difficulty in concentrating, 
and continual . of t en purposeless movement of parts of the body. Tremor is 
common, as are hype ractive reflexes and emotional di splays. Development of 
psychosis is sometimes seen. 
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Pargyline has been reported to produce a feeling of "well-being" in 
hypertensive patients (Horwitz and Sjoerdsma, 1963). Its effects in de-
pressed or schizophreni c pat ients are variable. however. Sharpley ~ !.!,. 
(1964) reported that in a double~blind study on 80 chronic psychiatric 
patients , mostly schi zophrenic . ne i ther pargyline nor tranylcypromine (a MAO 
inhibitor) effectively improved or worsened the psychiatric condition. Barsa 
and Saunders (1964) administered pargyline or tranylcypromine in combination 
with phenothiaz ine tranquillizers to 28 female schizophrenic patients. In 
three studies 82 comparisons were made : in 9 instances pargyline was super-
ior to tranylcypromine ; the reverse was true in 42 instances, and the drugs 
were judged equally effective in 31 instances. Drug effectiveness was 
evaluated by observing whether the pat ients became more alert and interested 
in the environment. The investigators concluded that pargyline combined 
with an antipsychotic tranquillizer is at times effective in schizophrenia, 
but not so effect i ve as tranylcypromi ne. 
Turner and Merlis (1964) administered pargyline and dihydroxyphenyl-
aline (DOPA) to psychotic pat ients on the assumption th.at increases in brain 
norepinephrine might lead to increased confidence and awareness. There re-
sulted some improvement in mood, resembling the effects of amphetamine but 
of longer durat ion. Other investigators also subscribe to this "catechola-
mine theory of affective disorders" which proposes, according to Klerman 
~ !.!.· ( 1964) " that depressed patients have an absolute or relative deficiency 
of central nervous system (CNS) catecholamines and that conversely, patients 
with elation have an excess of CNS catecholamines". The discovery that 
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reserpine depressed CNS levels of serotonin and norepinephrine and at the 
same time exhibited a tranquillizing effect apparently prompted the develop-
ment of this concept. Unlike Turner and Merlis, however , Klerman ~al. 
could not demonstrate that administration of phenelzine, a MAO inhibitor, 
plus DOPA elicited any reversal of psychotic depression. They suggested 
that perhaps orally-.adnini..stem:i DOPA does not enter the brain as rapidly as is 
supposed. 
( ) · · d c14 · 11 22 d Felrstein ~ aL 1964 adm1n1stere -serotonin ora y to e-
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pressed patients and to 22 normal volunteers; urinary levels of C -5-
hydroxyindoleacetic acid in these two groups were not significantly different, 
suggesting that MAO activity in unmedicated depressed patients is not re-
duced. Serotonin, however, does not enter the brain appreciably (Brodie, 
1958); thus, no conclusions concerning MAO levels in the brains of depressed 
patients can be drawn from this work. 
It thus appears that therapy with MAO inhibitors alone exerts vari-
able and inconsistent effects in depressed patients. Indeed, Barsa and 
Saunders (1964) pointed out that the MAO inhibitors frequently cause an 
increase in psychotic symptoms. But when used in conjunction with other 
drugs, especially antipsychotic tranquillizers or DOPA, the MAO inhibitors 
are apparently capable of relieving depression in some patients. 
Several recent studies relating MAO inhibitors to animal behavior are 
of interest. Poschel and Ninteman (1964) showed that MAO inhibitors, in-
eluding pargyline, produced marked increases in self-stimulation in rats 
trained to press a lever for rewarding electrical stimulation of the lateral 
hypothalamus. Mantegazza and Riva (1964) reported that treatment of mice 
with iproniazid plus beta-phenylethylamine produced increases in spontaneous 
gross activity as measured in photoelectric recorder-activity cages. This 
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effect, however 9 was not seen in rats . van Rossum and Hurkmans (1963) 
reported that pretreatment o.f mice with pargyl i ne reverses the sedative 
effect of alpha- me thyldopa . Moreover 9 a few hour s af t e r inje ction of the 
alpha-methyldopa a strong central excitation occurs , as measured in photo-
electric activity cages equipped with pulse shapers. 
Everett and Wiegand (1962) found increasing degrees of general motor 
activity in mice after administration of pargyline plus DOPA. Single-beam 
photoelectric recorder- activity cages were employed for the study, using 
4 mice per cage. Using an arbitrary program for rating activity by gross 
observation Everett and Wiegand were also able to demonstrate that mice re-
sponded to increasing acute doses of pargyline and DOPA by becoming more 
aggressive. Intraperitoneal (i.p.) administration of 100 mg/kg of pargyline 
HCl followed four hours later by administration of 100 mg/kg of DOPA produced 
aggressive attacking and fighting in mice. The dose-response curve of the 
combined drugs correlated both with increasing levels of brain dopamine and 
with increasing inhibition of MAO. Pargyline alone produced no change in 
activity in mice even at the same acute dose as above; brain dopamine was 
only slightly elevated. These results and earlier work by Everett (1961) 
suggest that increases in alertness and aggressiveness may be related to in-
creases in brain amines and also to decreases in brain MAO activity. 
Daily i.p. injecticn of rats with pargyline HCl at a dose of 25 mg/kg 
for 25 days was reported to result in reduced gross activity (Carrier and 
Buday, 1963). More recently Guarino ~ !!..!.· ( 1964), using the same daily dose, 
found general muscular tenseness in 13-253 of the rats while being handled 
or injected; this effect was first noted after 23 days of daily treatment 
and continued to the end of the 32-day study. 
The work of Carrier and Buday (1963) showed that rats receiving daily 
doses of 25 mg/kg of pargyline HCl and fed a 23 thyroid diet ad lib. appeared 
--
more depressed than animals receiving either drug alone. This work is 
interesting in view of the reported increases in apathy seen when both 
20 
thyroid and MAO inhibitors were administered to depressed patients (Kline, 
1961) . Working with mice, however, Reid (1963) found no changes in loco-
motor activity after treatment with pargyline, thyroid or both of these agents. 
E. The Effects of Thyroid Hormones~ Monoamine Oxidase 
Monoamine oxidase , IUB 1.4.3.4; Monoamine : oxygen oxidoreductase 
(deaminating), is a cuproprotein that acts on primary, secondary and tertiary 
amines, in combination with H2o and o2 , to yield an aldehyde + NH3 + H2o2 . 
Oxygen acts as the acceptor. (Enzyme Nomenclature, 1965). Although MAO is 
secondary to COMT in catabolizing circulating adrenergic amines it is appar-
ently the main enzyme for the inactivation of these monoamines in the central 
nervous system (Sice, 1962) . About 703 of MAO activity is found in the mito-
chondria (Baudhuin, !:.! !.!.·• 1964). 
"One can hardly imagine a more conflicting series of reports than 
those existing on the effects of thyroid feeding on monoamine oxidase activity" 
(Harrison, 1964). Since the appearance of the now-classic paper of Spinks 
and Burn (1952) several investigators have reported on the effects of admin-
istered thyroid hormones on MAO activity in liver, heart and brain. In these 
studies there were considerable differences in types and sex of animals used, 
thyroid doses, enzyme preparations and assay methods. These differences 
have undoubtedly contributed to the confusion that follows when comparisons 
are made of the results of different workers. Much of this confusion may be 
eliminated, however , if one groups together all the available data for each 
organ studied and subdivides according to animal, sex and treatment. An 
attempt to do this is presented below. 
Unless otherwise noted below, the method of MAO assay used in the 
studies to be described was the Warburg manometric technique with tyramine 
as substrate. Oxygen utilizat i on was measured. 
MAO activity in the tissues of thyroid- treated animals is expressed 
as per cent change from control values. These percentages were taken from 
the reports or, if not given, calculated from the data presented. 
1. The Effect of Thyroid on Liver MAO 
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a) Burn and Spinks (1952). Spinks and Burn (1952). Rabbits were fed 
200 mg dried thyroid daily for 14 days. Tissue was frozen at -15°C until 
use. The assay for MAO activity was carried out on a 53 homogenate in 
0.067 M phosphate buffer (pH7.4), and disclosed a 163 (P = 0.015) decrease 
from control values. 
b) Trendelenburg (1953). Rabbits were treated and fresh homogenates 
were prepared as above (a). The assay for MAO activity disclosed a 103 
(P = 0.05) decrease from control values. 
c) Zile and Lardy (1959). Male rats were sustained for 3-4 weeks on 
a diet containing 23 desiccated thyroid. The assay for MAO activity was car-
ried out on mitochondria isolated in 0.25 M sucrose. The mitochondria were 
either fresh, or frozen and thawed for assay. The assay disclosed a 513 
(P = 0.015) decrease from control values. 
d) Zile, (1960). Male rats were injected (s.q.) with Na thyroxine· 5H2o, 
2.5 mg/kg daily for 10 days. The assay for MAO activity was carried out on 
mitochondria isolated in 0.25 M sucrose, and disclosed a 523 decrease from 
control values. 
e) Novick (1961). Rats of mixed sex were sustained for 12 days on a 
diet containing 23 desiccated thyroid. The assay for MAO activity was car-
ried out on mitochondria suspended in 0.067 M phosphate buffer (pH7.4), and 
disclosed a 503 depression from control values. 
f) Wurtman ~ !,!.(1963). Male rats were injected (i.p.) with Na 
thyroxine, 1 mg/kg, daily for 7 days. The assay for MAO activity was carried 
out on fresh homogenates in i sotonic KCl. The produc tion of c14-
14 indoleacetic acid from C -tryptophan was mea sured. No change from control 
values was seen. 
g) Wurtman et al.(1963). Female rats were injected (i.p.) with Na 
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thyroxine, 1 mg/kg daily for 10 days . The assay for MAO activity was carried 
out as above (f), and disclosed a 303 increase (P = 0,05) over control values. 
h) Wurtman ~ .!!.!· (1963). Female rats were injected (i . p.) with Na 
thyroxine, 5 mg/kg daily for 5 days. The assay fo~ MAO activity was carried 
out as above (f), and disclosed a 163 decrease ( P < 0.05) from control values. 
i) Utley (1964) . Female rats were injected (s.q.) with 1-triiodothy-
ronine (l-T-3), 0.3 mg/kg daily for 12-14 days. The assay for MAO activity 
was carried out on fresh homogenates in 0.067 M phosphate buffer (pH = 7.4), 
and disclosed a 153 decrease (P = 0.005) from control values. 
j) Reid (1963). Male mice were injected (i.p . ) with suspended thy-
roid powder, 2 mg/kg daily for 14 days. The assay for MAO activity was car-
ried out on a mitochondria- microsome mixture suspended in 0.25 M sucrose and 
prepared from frozen tissue. No change from control values was noted. 
2. The Effects of Thyroid~ Heart MAO 
a) Zile (1960). Male rats were injected (s . q.) with Na thyroxine: .sH2o, 
2.5 mg/kg daily for 10 days . The assay for MAO activity was carried out on 
mitochondria isolated in 0.25 M sucrose. Some of the studies were done using 
a frozen, thawed preparation . No change from control values was noted. 
b) Novick (1961) . Rats of mixed sex were sustained for 12 days on a 
diet containing 23 desiccated thyroid. The assay for MAO activity was car-
ried out on mitochondria suspended in 0.067 M phosphate buffer (pH 7.4), and 
disclosed a 753 increase over the controls. 
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c) Novick (1961). Rats of mixed sex were injected (s.q.) with l-T-3, 
0.15 mg/kg daily for 8 days. The assay for MAO activity was carried out as 
above (b), and disclosed a 703 increase over the control values. 
d) Skillen~.!!...!· (1962). Male rats were sustained for 21 days on a 
diet containing 0.153 desiccated thyroid. The assay for MAO activity was 
carried out by measuring fluorometrically the disappearance of serotonin. 
Homogenates prepared in water and frozen at -15°C for 24 hours before assay 
were used. No change from control values was noted. 
e) Skillen~!.!· (1962). Female rats were treated and MAO assays were 
carried out as above (d). The assays disclosed a 1733 increase (P = 0.03) 
over control values. 
f) Utley (1964). Female rats were injected (s.q.) with l-T-3, 
0.3 mg/kg kaily for 12-14 days. The assay for MAO activity was carried out 
on fresh homogenates in 0.067 M phosphate buffer (pH 7.4) and disclosed a 283 
increase (P = 0.005) over control values. 
3. ~Effect .2f Thyroid~ Brain MAO 
a) Zile (1960). Male rats were injected (s.q.) with Na thyroxine, 
2.5 mg/kg daily for 10 days. The assay for MAO activity was carried out on 
fresh homogenates in 0.25 M sucrose. No change from control values was noted. 
b) Reid (1963). Male mice were injected (i.p.) with suspended thy-
roid powder, 2 mg/kg daily for 14 days. The assay for MAO activity was car-
ried out on a mitochondria-microsomes mixture suspended in 0.25 M sucrose 
and prepared from frozen tissue. No consistent changes from control values 
were noted. 
4. Summary 
From the foregoing tabulation several interesting trends may be seen. 
Liver. In studies (a),(b),(c),(d),(e) and (i), a decreased MAO 
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activity was seen in thyroid=treated animals. In these s ix studies the 
Warburg technique was employed to measure o2 utilization with tyramine as 
substrate , and in al l six enzyme preparat i ons the mitochondria were subjected 
to treatment resulting in swelling , aging or lysing. Type or sex of animal 
employed appeared not to influence the results of these six studies. 
In studies (g) and (h) anomalous effects were seen in female rats 
Very high doses of thyroxine (5 mg/kg) depressed MAO activity, but the same 
dose (1 mg/kg) that had no effect in male rats in study (f) effected a 303 
increase in MAO activity in female rats. Studies (f), (g) and (h) were 
carried out as part of one project (Wurtman !:.,! ~·· 1963) and the same assay 
method was employed in all three sections. 
Heart. In male rat hearts , studies (a) and (d) showed no change in 
MAO activity after thyroid treatment. Different assay methods were used, but 
both employed preparations in which mitochondria are generally swollen, aged 
or lysed. 
In female rat hearts, studies (e) and (f) increases in MAO activity 
were seen after thyroid treatment. Different assay methods were used, but 
beth employed enzyme preparations in which the medium was hypotonic to mito-
chondria. Since both sexes of rats were used in studies (b) and (c), the 
increased MAO activity was probably due to the presence of female rats with 
higher MAO activity. 
Brain. No changes in brain MAO were induced by thyroid treatment. 
It appears , in summary , that thyroid-induced depression of MAO in 
liver was seen only when manometr ic te chniques were employed on enzyme prepa-
rations in which mitochondria were not completely intact. Thyroid-induced 
increases of heart MAO are apparently seen only in female rats. 
III. INVESTI GATION 
A. Objectives 
The point of departure for this study was the reported retardation 
and apathy resulting from concurrent thyroid and monoamine oxidase (MAO) in-
hibitor therapy in depressed patients (Kline, 1961). An experiment of broad 
design was consequently evolved in order to simultaneously evaluate, in rats, 
certain parameters in which drug-induced changes might in turn affect be-
havior. 
No real correlation necessarily exists between the effects of drugs 
in depressed patients and in normal laboratory rats. Consequently it was 
necessary to first establish a reliable method for measuring the behavioral 
responses of normal rats to chronic treatment with thyroxine and pargyline 
hydrochloride, a potent non-hydrazine MAO inhibitor. Use of a reliable method 
for measuring activity would permit one to carry out the main objective of 
this work: to determine if, under conditions of chronic thyroxine and pargy-
line treatment in rats, a correlation exists between changes in behavior and 
changes in certain physiological or biochemical parameters thought most likely 
to be affected by these drugs. 
In this study the effects of chronic treatment with thyroxine, pargy-
line, and combined thyroxine and pargyline were determined on systolic blood 
pressure, body weight gains, locomotor activity, urinary sodium and potassium 
excretion and terminal MAO activity in brain and liver. 
B. rMaterials ~Methods 
1. General Considerations~ Daily Protocol 
In each study rats were divided into four groups for daily intraperi-
toneal injection with thyroxine, pargyline, combined throxine and pargyline, 
and vehicle, respectively. 
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Male, adult albino rat s of t he Sprague-Daw l ey st r a i n1 were distributed 
three to a cage in standard me t abol i sm cage banks2 and hou sed i n a soundproof 
room maintained at abou t 503 r e lative hJmi d i t y . Room temperatur e, measured 
by a Tempscribe recording thermometer3 was maintained at 22.2 : 0.5°C. The 
room was dimly lighted from 7 am to 7 pm daily. All studies except blood 
pressure determinations were carried out in this room, and all animals used 
in these studies were housed here both before and during experimentation. 
The animals were each offered 21 g of ?urina4 rat chow daily at 6 pm. 
Unlimited access to water was provided by wiring two jars of 255 ml total 
capacity into each cage. All animals were weighed to the nearest gram and 
injected daily from 9 am - 12 noon. Water jars were refilled and the urine 
collecting apparatus was cleaned and r ese t at this time . 
Drugs were prepared for intraperitoneal injection as follows: Na 
l-thyroxine 5 was suspended daily before use in glass-distilled water in a 
concentration of 1 mg/ml or 0.5 mg/ml. Pargyline HC16 was dissolved in a 
concentration of 25 mg/ml glass-distilled wate r . There was no mixing of 
drugs: animals receiving both thyroxine and pargyline had a separate injec-
tion of each drug. Animals treated with one of the drugs or with the vehicle, 
glass-distilled water , were given a second , sham injection. 
1. Charles River Breeding Farms, North Wilmington, Massachusetts. 
2. Wahmann Mfg. Co., Baltimore, Maryland. 
3. Bacharach , Pittsburgh, Pennsylvania. 
4. Ralston Purina, St. Louis , Missouri. 
5. Calbiochem, Los Angeles , California. 
6. Kindly supplied by Dr. R. B. Hasbrouck and Mr. Dale Giddings, Abbott 
Laboratories, North Chicago, Illinois. 
Drug doses were as follows: 
Pargyline HCl 
Na !~thyroxine 
Vehicle , glass-
distil led water 
25 mg/kg body we i ght , i.p. daily, 
1 mg or 0. 5 mg/kg body weight, 
i. p. daily. 
1 ml/kg body weight, i.p. daily. 
This investigation was carried out in two separate phases. In both 
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phases , however , animal housing and daily protocols were as described above. 
In phase l • i nvolving 30 rats , the effects of chronic administration 
of thyroxine , pargyline, combined thyroxine and pargyline, and vehicle on 
blood pressure were evaluated. In addition, weight gains were analyzed and 
terminal MAO activity was determined in brain and liver. 
In phase ~ . involving 142 rats, the effects of chronic administration 
of thyroxine , pargyline, combined thyroxine and pargyline, and vehicle on 
gross activity, urinary sodium and potassium and weight gains were evaluated. 
Terminal MAO activity in liver and brain was also determined. 
A preliminary study , involving 24 untreated rats, was first carried out 
in order to evaluate the method of analyzing gross activity. 
Each phase of this study is divided into a principal and a supplemen-
tary group of animals. The principal animals were placed in the cages so 
that the initial weight range of the 3 rats per cage would not exceed 5 g. 
Moreover, the overall initial weight range in the 24 and 96 animals in each 
respective principal group was 34 and 57 g, respectively. The supplementary 
groups were composed of heavier rats wi th somewhat wider weight ranges. For 
this reason weight gain studies were carried out only on the principal groups 
in each phase of this study. 
These studies are summarized in the following chart. 
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SUMMARY OF EXPERIMENTAL IES IGN 
PHASE 1 PHASE 2 
--
1. Number of Rats : 30 142 
2 . Initial Weight Ranges ( g): 
Principal Group (24) 161- 195 ( 96) 145-202 
Supplementary Group ( 6) 214- 297 ( 46) 202-327 
Ove ra 11 Ranges (30) 161-297 (142) 145-327 
3 . Blood Pressure Study : Yes No 
4 . Gross Activity Study : No Yes 
5. Urinary Na+ and K+: No Yes 
6. Weight Gains: Principal Principal 
Group (24) Group ( 96) 
7. Terminal MAO: Yes Yes 
a. Length of Study : 
Pretreatment Period 11 days None 
Drug Treatment Period 27 days 12 days 
(days 0-26 incl.) (days 0-11 incl.) 
9 . Daily i.p. Treatment : 
Na Thyroxine, 1 mg/kg Days 0- 19 incl. Days 0-4 incl. 
Na Thyroxine , 0 . 5 mg/kg Days 20-26 incl. Days 5-11 incl. 
Pargyline HCl , 25 mg/kg Days 0- 26 incl. Days 0-11 incl. 
Vehicle , 1 ml/kg Days 0-26 incl. Days 0-11 incl. 
PRELIMINARY STUDY 
1. Number of Rats : 24 
2. Initial We i ght Range ( g): 133-178 
3. Purpose : Evaluation of Gross Activity Method 
4. Length of Study : 22 days 
5. Drug Treatment : None 
2. Blood Pressure Study 
The effects of da i l y trea t ment wi t h t hyroxi ne , pa r gyl ine, combined 
thyroxine and pargyl ine ~ a nd vehic le on the s ystolic blood pr essu re of rats 
were determined. This study, a part of phase 11 , was carried out in an 
Environtrol constant-temperature chamber maintained at 28°C, in which low 
humidity was maintained by means of rapid turnover of air in the chamber. 
Rats were fed and housed as described previously; only during the actual 
determinations were they removed to the Environtrol chamber . 
29 
The tail cuff method of indirect systolic blood pressure determination 
was used. Rats were removed from their cages and placed in an incubator box 
at 4o 0 c for 15-20 minutes. After incubation each rat was allowed to enter a 
clear plastic chamber2 with d i mens i ons 23 cm x 7 cm x 5 cm. This chamber is 
closed at the far end but provided with a movable piston in order to regulate 
the internal length. The sliding partition at the open end of the chamber wa s 
then put into position, leaving only the rat ' s tail protruding. After a few 
minutes in the chamber the rat generally became calm. 
An inflatable tail-cuff
3
, connected to a Physiograph manometer system4 , 
was placed about 1 cm from the base of the tail. Distal to the cuff the tail 
was passed through a small plastic holder des i gned so that when the screw 
clamp was slightly tightened the tail came into contact with a Beckman micro-
phone transducer. 5 The transducer lead was fed into a Beckman Infraton5 
1. See Summary of Experimental Design , Page 28. 
2. Constructed by Mr. David Coates, Dept. of Pharmacology, University of 
Rhode Island. 
3. Harvard Instruments, Cambr idge, Massachusetts. 
4. E & M Instruments , Houston, Texas. 
5. Beckman Co. , Palo Alto , Cal i forn ia. 
signal divider set for maximum pulse 0 and the lnfraton output lead was 
plugged into the di re c t current input of an HP osc i lloscope 1 set at a sweep 
time of 20 mse c/cm. 
This system converts systolic pressure pulses in the rat's tail to 
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peaks on the oscilloscope screen. Squeezing the rubber bulb of the manometer 
system increases pressure in the system ; the cuff becomes inf lated, and con-
sequently the peaks disappear as tail circulation distal to the cuff is cut 
off . By opening the pressure escape valve slightly, pressure in the manometer 
system can be reduced at will . As tail circulation is restored peaks begin 
to appear again on the screen. At this point the pressure reading on the 
manometer dial is considered to be the systolic blood pressure, because it 
is assumed that for distal circulation to be restored the pressure in the tail 
arteries must be slightly greater than the pressure in the manometer system. 
The recorded blood pressure of a rat on a given day was the average of 
at least 3 successive determinations. It was found that once the animal was 
quiet, successive determinations fell into a range not exceeding 4-5 mm Hg. 
In the principal blood pressure study 24 rats caged and fed as de-
scribed above were divided into four groups of 6. Blood pressures were 
determined on four separate days before drug treatment was begun: days -11, 
-9, -7, and -2. The first day of drug treatment was designated day o, and 
blood pressures were determined on days 2, 7, 10 , 12, 16 and 19 of daily drug 
treatment. Daily drug doses (i.p . ) from day 0 were as follows: vehicle, 
1 ml/kg; pargyline HCl , 25 mg/kg; Na thyroxine, 1 mg/kg. Animals receiving 
both drugs received the full dose of each. 
For each day that blood pressure determinations were made, the data 
1. Model 130 B., Hewlett-Packard Co ., Palo Alto, California. 
from each of the three drug-treated grou ps were separa t ely compared to the 
vehicle-treated group by means of Student's " t" test ( Snede cor , 1956) . 
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The data from the pre-treatment pe r iod (days - 11 , -9 , - 7 and -2) were 
similarly analyzed . But it was found t hat in this pre-drug period no differ-
ence (P ~ 0.05) existed between the group designated as the future vehicle-
treated group and each of the three groups destined to receive drugs. These 
data were consequently pooled so that for each of the four days in the pre-
treatment period one mean :!: S. D. was obtained. 
Because of the high mortality in the combined-drug group a second, 
supplementary blood pressure study was undertaken using heavier animals 
(214-297 g). Two groups , vehicle-treated and combined-drug treated, were used. 
Blood pressure determinations were made on days -6 and -4 before drug treat-
ment was begun, and again on day 3 of drug treatment . 
3. Activity Studies 
Four multibeam "Actophotometer" units1 were employed in determining the 
effects of daily treatment with thyroxine , pargyline, combined thyroxine and 
pargyline, and vehicle on the locomotor activity of rats. 
The actophotometer consists of a circular cage 31 cm deep and 33 cm 
in diameter. Two centimeters up from the grid floor are 12 holes spaced 
equally apart around the inside diameter of the cage; from these holes six 
light beams pass through red filters and cross the cage to activate six re-
spective photoelectric cells. When any one of these light beams is inter-
rupted a digital counter advances one unit. Animals moving about in the cage 
interrupt the light beams , causing the counter to advance; in this way, counts 
per unit time can be used as a measure of locomotor ac t i v ity . 
1. Metro Scientific , Inc., Carle Place , Long Island City, New York . 
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The light beams and photocells were adjusted for maximum sensitivity 
by varying the angle of incidence of light to the photocell and by adjusting 
voltage to the counter relay and to the photocells. It was found that each 
cage has its own sensitivity characteristics, resulting in varying total 
counts per unit time from one cage to another . Watzman (1964) found similar, 
inherent sensitivity differences among actophotometer units. It is not prac-
tical to attempt a calibration of four cages; therefore, comparisons from 
one cage to another cannot be made. Rather, the experiment is designed so 
that data from both vehicle-treated and drug-treated animals are obtained from 
~~cage. Thus for~ cage one must have control values. 
The four actophotometer cages were located in the same soundproof room 
described above. The counters were located in an adjacent room. Because ani-
mals were kept in the actophotometers for six-hour periods, these units were 
fitted with standard water bottles in order to insure a constant supply of 
water. 
All animals used in the activity studies were placed on the same hous-
ing and feeding schedule as described above. 
The same design was employed for all activity studies. Three animals 
were removed from their cage and immediately placed in the actophotometer; 
grids were then placed on top of each unit to prevent animals from escaping. 
The room was quickly secured and the counters in the adjacent room were turned 
on. A maximum time of three minutes elapsed between placing of animals in the 
four cages and turning on the four counters to begin recording counts. A clock 
was simultaneously set. 
This procedure was always started between 11:30 am and 12 noon. Total 
cumulative counts appearing on the counters from time 0 were recorded every 
30 minutes for six hours (i.e., once counting was begun the counters were never 
reset). 
33 
After the s i x hour period had elapsed the animals were returned to 
their respective cages. 
'I\Jo separate act i vity stud i es were carried out. The preliminary study1 
employed 24 untreated, uninjected rats d "vi ded into 2 groups of 12 each. 
Each group was subdivided into 4 units of 3 animals each, and each unit of 
3 animals was assigned to be run every other day in one of the four acto-
photometers . On day 1 of the study the 12 animals in group 1 were put into 
their respective actophotometers and counts were taken as described above. On 
day 2 the 12 animals in group 2 were similarly run , and on day 3 the animals 
in group 1 were again placed in the actophotometers. This alternation con-
tinued for a total of 22 days, resulting in 12 daily sets of data per cage per 
group (days 1,3 , 5 , 7, .. . 21 for group 1 and days 2,4,6 , 8, ..• 22 for group 2). 
The second study was carried out using the principal group of phase ~l. 
The 3 animals in each unit of group 1 were injected daily at 9:45 am with 
vehicle, thyroxine , pargyline , and combined thyroxine and pargyline, respec-
tively. The 3 animals in each of the 4 units of group 2 were injected with 
vehicle. This study was run for 11 days, resulting in 6 daily sets of data 
per cage for group 1 (days 0 , 2, 4 p 6, 8 and 10) and 5 daily sets of data per 
cage for group 2 (days 1 , 3, 5, 7 and 9). 
In the drug-treated groups deaths occasionally occurred . Only one rat 
died during an actophotometer run; data for that cage was discarded for that 
day. If animals being used in the activity study died during the night or 
early moring the entire unit of 3 was replaced with another unit of animals 
identically treated . 
1 . See Summary of Experimental Design, Page 28 • 
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Recording of cumu lative counts every 30 minutes for six hours resulted 
in 12 figures per cage per day . From these f i gures the counts that had accumu-
lated during each of the twelve 30~mim.1. te increments were determi ned simply by 
subtracting the 30-minute total count from the 60~minute total count, the 60-
minute count from the 90~minute count, and continuing successively. There 
resulted , then , 12 total counts, and 12 incremental counts of 30 minute periods 
per cage per day. 
The data from each of the two studies were analyzed in two ways: 
a) Incremental Counts ~ ~Minutes 
For a given actophotometer , two groups of animals were run on alternate 
days, resulting in two sets of data as indicated above . Using Student's "t" test 
(Snedecor, 1956) the data from each 30-minute interval of group 1 was compared 
to the data from the corresponding time~interval of group 2. 
b) Total Counts~~ 
Total counts were recorded from each unit every 30 minutes, as indicatP.d 
above. But only the total elapsed counts~~ were analyzed. The method 
of analysis was identical to that used for the 30-minute incremental data. 
4. Urinary Sodium and Potass i um Stud i es 
1 This work , a part of phase 2 , evaluated the effects of daily treatment 
with thyroxine , pargyline, combined thyroxine and pargyline, and vehicle on 
the daily output of sodium and potassium in the spontaneously-voided urine of 
rats. 
From 9-11 am daily , animals were injected and drinking- water vessels 
were filled. The urine~collecting funnels were fitted with cot t on plugs at 
the apex; the screens designed to keep food fragments and droppings out of the 
1. See Summary of Experimental Design , Page 28. 
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funnels were put into place , and finally the funnels were secured under the 
cages. Bottles were placed under the funnel spouts at 11:30-11:45 am, and 
urine collection c<mmenced. The rats were fed as usual at 6 pm, without 
disturbing the funnels or bottles. At 9 am the next day each bottle was re-
moved from the collection site; tbe contents were measured to the nearest 
0.5 ml and a sample was stored in a stoppered glass tube in the refrigerator 
until assay. The funnels, bottles and screens were thoroughly washed and 
allowed to dry. At 11:30 am, urine collection began again. 
A record was kept of daily water consumption in each cage. These 
values are not reported, however, because they do not reflect water actually 
consumed. The rats carried on a great deal of splashing and washing in the 
drinking water, especially in the thyroxine-treated groups; consequently it 
was impossible to determine how much water was consumed. Much of the spilled 
water appeared in the urine-collecting bottles. For this reason no conclusions 
with respect to the effects of the drugs on urine volume could be drawn. 
This splashing had no effect on sodium and potassium determinations, 
since these are reported simply as total mEq/cage/day and not as a concentra-
tion of ions in urine. 
Urine samples were analyzed for s odium and potassium on the Advanced 
flame photometer1 using the lithium internal standard method. 
Stock solutions of NaCl (1000 mEq/l) and KCl (100 mEq/l) were prepared 
using glass-distilled water. From these, standard concentrations of Na+ 
(10-160 mEq/l) and K+ (1-10 mEq/l) were prepared by suitable dilution with 
glass-distilled water. A 1:2000 solution of Li2so4 (internal standard solution) 
in glass-distilled water was prepared. Standard cur ves were made by using 
1. Model llB, Advanced Instruments, Inc . , Newton Highlands, Massachusetts. 
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the standard concentrations of the ions, diluted 1:100 with the lithium 
sulfate solut i on . Urine was similarly dilu ted with this solution: 1:100 
for the sodium assay and 1 : 2000 for the potass ium assay. Each urine sample 
was read against the standard curve. 
Total output of Na+ or K+ in terms of mEq/3 rats/day (i.e., mEq/cage/ 
day) was determined by multiplying the Na+ or K+ concentration in the urine 
aliquot by the total volume collected for that cage. 
Thus, for each day of urine collection there resulted data from 
several cages in each of the four treatment groups. For each day the data 
from control (vehicle-treated rats) cages were compared to the data from each 
of the three drug~treated groups by means of Student's "t" test 1 Snedecor, 1956). 
5. Weight Gain Studies 
The effects of daily treatment with thyroxine, pargyline, combined 
thyroxine and pargyline , and vehicle on the individual body weights of rats 
were determined. 
All animals used in this work were routinely weighed daily, to the 
nearest gram, on an Ohaus small-animal balance 1• Each rat was marked for 
identification and individual records were kept of the daily weights. Be-
cause of the small range of their initial weights the animals from the 
2 principal groups of phase 1 and phase 2 were used for weight gain analysis. 
For each animal , then, there was compiled a record of daily weight from 
day O, the beginning of the study. Three methods of data analysis were em-
ployed . 
a) Daily Weights. For each day of the study, the individual daily 
1. Ohaus Scale Corp ., Union, New Jersey. 
2. See Summary of Experimental Design, Page 28. 
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weights of all animals in each treatment group were compared to the indi-
vidual daily weights of the control group. 
b) Cumulative Daily Weight ~ ~ Da_y ~- These were determined 
by subtracting the weight of each animal on day O from its weight on each of 
the remaining days of the study. Daily comparisons were made, as above, be-
tween the control group and each treatment group. 
c) Daily Weight Gains. These were determined by subtracting the 
weight of each animal on one day from its weight on the next day. This was 
done for each day of the study. Daily comparisons were made, as above, be-
tween the control group and each treatment group. 
Student's "t'1t test (Snedecor, 1956) was used to compare these data. 
The spectrophotometric MAO assay method of Weissbach ~ al. ( 1960) was 
modified for the determination of MAO activity in brains and livers of rats 
treated daily with thyroxine, pargyline, combined thyroxine and pargyline, 
and vehicle, respectively. 
In this assay the disappearance of kynuramine 1 at 360 ~ is followed 
in the Beckman DU spectrophotometer. The action of MAO on kynuramine is 
postulated to be the following: 
H 
2,4-dihydroxyquinoline 
H 
4-hydroxyquinoline 
1. Kynuramine dihydrobromide, Regis Chemical Co., Chicago, Illinois. 
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As kynuramine absorbance a t 360 ~ de crea ses , an absor bance peak at 
310- 335 ~ develops , and the f inal s pectrum of an incuba t ion of kynuramine 
with rabbit liver homogena t e close l y re sembles the spectrum of 4- dydroxyquino-
line , the postulated product (Weissbach ~ !.!,..,, 1960). 
Preliminary exper i ments wi th rat bra i n and liver homogenates satis-
factorily reproduced Weissbach ' s data , showing that kynuramine disappearance 
at 360 ny.i is linear with time . But the overall experimental design involved 
the sacrificing , on the last day of the study, of many animals on whom MAO 
assays were then to be carried out . Thus it was important to develop an assay 
method that would permit storing , for subsequent analysis, of MAO or MAO-
containing tissues from these animals . 
The majority of MAO activity is found in the mitochondria (Baudhuin 
~!.!.·~1964 ; Weissbach~!].,1960 ; Zile and Lardy, 1959; Hawkins, 1952). 
Seiden and Westley (1962) reported a method for isolating and lysing brain 
mitochondria for subsequent ultrasound treatment to release soluble MAO. 
The soluble MAO was then assayed by the Weissbach method. Here, however, the 
Weissbach method was adapted for use with lysed, rehomogenized mitochondria 
prepared by a slight mod i f ication of Seiden and Westley's procedure. Further-
more , it was found that storage of a suspension of lysed mitochondria at 
- 40°C for as long as three months d i d not affect their turnover of kynuramine. 
Finally, the assay was run at 30°C instead of at room temperature. The tem-
perature inside the DU cuvette chamber was maintained at 3o0 c ~ 0.5° by 
attaching to the instrument two Beckman Thermospacer 1 units connected to a 
Haake 2 water heater and circulator . 
1 . Beckman Instruments , Inc. , Fullerton, California . 
2. Haake , Gerruder , Berlin . 
a) Preparation of Mitochondria. Animals treated daily with 
thyroxine, pargyline, combined thyroxine and pargyline , or vehicle 1 were 
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• d • • 2 sacrifLced by ecapLtatLon. All subsequent procedures were carried out at 
o0 c. Each brain was quickly removed, placed in 10 ml of 0.25 M sucrose and 
homogenized in a pyrex homogenizing tube using a teflon pestle. 3 The homo-
genate was transferred to a 50 ml polypropylene tube and centrifuged4 at 
1500 x g for 6 minutes. The supernatant fluid, containing mitochondria and 
microsomes, was layered over 15 ml of 0.88 M sucrose in a 50 ml polypropylene 
tube and centrifuged at 18000 x g for 20 minutes. The resulting supernatant 
was aspirated out, leaving the mitochondrial pellet. The mitochondria were 
lysed when resuspended in 6.0 ml of 0.05 M phosphate buffer (pH 7.4) and 
dispersed in the buffer by rehomogenization. The lysed, resuspended mito-
chondria were transferred to a 12 ml polypropylene tube which was stoppered 
and stored at -4o0c until assay. 
MAO Assay. The tube of frozen, suspended lysed mitochondria was allowed 
to thaw and immediately placed in crushed ice. The temperature in the cuvette 
chamber of the DU spectophotometer was allowed to reach 30°C and maintained at 
this temperature throughout the assay. All constituents of the assay mixture 
were kept at 30°C in a water bath5 ; only the mitochondria were kept at o0c. 
1. See phase 1 and phase 2, Summary of Experimental Design, Page 28. 
2. Guillotine, Harvard Instruments, Cambridge, Massachusetts. 
3. Tri-R Homogenizer, Tri-R Instruments, Jamaica, New York. 
4. Servall Refrigerated Centrifuge, Model RC-2, Sorvall, Inc., Norwalk, 
Connecticut. 
5. Scientific Glass Apparatus, Inc., Bloomfield, New Jersey. 
Incubation mixtures were prepared in Beckman standard silica cuvettes by 
adding reagents in the following sequence : 
Reagent 
0.5 M phosphate buffer, (pH 7.4) 
O. 3 )JM kynuramine 
Water, glass-distilled 
Mitochondrial suspension 
Blank 
0.3 ml 
1.2 ml 
1.5 ml 
3.0 ml 
Exper imenta 1 
0.3 ml 
0.1 ml 
1.1 ml 
1.5 ml 
3.0 ml 
Immediately after the mitochondria were added, a clock was set and the 
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cuvettes were mixed by inversion and placed in the DU cuvette chamber. The 
instrument was set at 360 lllJl with a slit width setting of 0.1. Absorbance 
of the experimental cuvette was read against the blank approximately every 
3 minutes for 30 minutes. Initial absorbance was about 0.3. A curve was 
constructed from the data by plotting absorbance readings on the ordinate 
against time (in seconds) on the abcissa. Because of settling of particles 
in the cuvette, initial readings were sometimes erratic. For this reason 
these curves were constructed using the last 20 minutes of the 30-minute assay 
period. In this time interval the curves were linear in each case. 
A standard curve of kynuramine concentration against absorbance was 
constructed and found to be linear in the 0.05- 0.71 absorbance range. 
Protein Determination. The standard colorimetric biuret method of 
Gornall ~ ~.(1949) was used to determine protein content of an aliquot of 
each mitochondrial suspension. These determinations were carried out on the 
DU spectophotometer. 1.0 ml of the mitochondrial suspension was added to 
4.0 ml of biuret reagent, mixed and allowed to stand for 30 minutes. Readings 
were taken at 540 lllJl against a blank containing 1. 0 ml of water instead of 
mitochondria. Standard curves were prepared using bovine albumin protein 
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standard solution1 , and the prote i n content of the mitochondrial suspensions 
was determined by r eading aga ins t the s t anda rd curve . 
Method 2f Ca lculat i ng ~ Activi.!.l . Decrea se in absorbancy during 
the last 20 minutes of each 30-minute assay was determine d from the slope 
of the assay plot. This value was extrapolated to one hour and divided by 
the slope of the kynuramine standard curve (change in absorbancytJ.imol of 
kynuramine free base). This value was divided in turn by the amount of 
mitochondrial protein present in the cuvette to yield a rate of substrate 
turnover in terms of pmo 1 kynuramine/hr/mg protein. 
Determination of Mitochondrial Stability.!..££~ Assay. This prelim-
inary study was carried out on a suspension of mitochondria prepared as 
described above from 8 rat brains. An aliquot of the fresh preparation was 
assayed and the remaining aliquots were stored at -4o0 c for a~say at various 
intervals up to 3 months. 
A comparison was also made between the rate of kynuramine turnover by 
crude homogenates and by the mitochondrial preparation. 
b) Liver MAO Study. Slight changes were made in the brain MAO assay 
procedure described above in order to adapt it for use with liver mitochondria. 
Only the specific changes are noted here. 
Preparation 2f Liver Mitochondria. A modification of the method of 
Myers and Slater (1957) was used. Rats were sacrificed by decapitation; each 
liver was removed, placed in 0.25 M sucrose at o0 c and minced with scissors. 
The liver particles were washed with 0.25 M sucrose, suspended in a total 
volume of 35 ml in 0.25 M sucrose, and homogenized. The homogenate was cen-
trifuged at 300 x g for 10 minutes and the pellet discarded. The supernatant 
was centrifuged for 10 minutes at 2000 x g and the resulting supernatant was 
1 . Armour Pharmaceutical Co . , Kankakee, Illinois. 
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discarded. The remaining pellet was resuspended in 25 ml of 0 . 25 M sucrose 
and centrifuged at 4600 x g for 10 minutes; the resulting supernatant was 
discarded. The pellet was resuspended in 6.0 ml of 0.05 M phosphate buffer 
(pH 7.4) and rehomogenized. This final suspension was stored in a stoppered 
12 ml polypropylene tube at -4o0 c until assay. 
~Assay. The assay for MAO in liver mitochondria was carried out as 
described above for brain mitochondria. Because a smaller volume of suspended 
liver mitochondria was used, cuvettes were prepared as follows: 
Reagent Blank Experimental 
0.5 M phosphate buffer (pH 7 .4) 0.3 ml 0.3 ml 
0.3 uM kynuramine 0.1 ml 
Water, glass-distil led 2.6 ml 2.5 ml 
Mitochondria 1 suspension 0.1 ml 0.1 ml 
3.0 ml 3.0 ml 
All other procedures used in the assay of liver MAO did not differ from 
the methods used for brain MAO. 
I V. RESULTS 
All tables and figures are contained in this section. 
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TABLE 1 
PRINCIPAL BLOOD PRESSURE STUDY': THE EFFECTS OF CHRONIC THYROXINE AND 
PARGYLINE TREATMENT ON SYSTOLIC BLOOD PRESSURE IN MAI.E ALBINO RATS 
-11 
-9 
-7 
-2 
2 
7 
10 
12 
16 
19 
118 ± 10 
( 6) 
115 ± 6 
( 6) 
109 ± 6 
( 6) 
ll 
114 :t 10 
d (6), N.S. 
123 ! 7 
(6), N.S. 
115 :!: 10 
(6), N.S. 
111 ± 15 
(6), N.S. 
ill 
120 :!: 3 
(5), N.S. 
118 :! 7 
(6), N.S. 
119 :t 11 
(6), N.S. 
116 ± 10 
(6), N.S. 
Daily Drug Injection Began -2!!. Day.£.:. 
VERICI.E 
107 :! 3 
( 6) 
112 ± 9 
( 5) 
121 + 13 
( 6) 
113 + 7 
( 6) 
117 + 11 
( 6) 
113 ± 6 
( 6) 
THYROXINE 
124 :! 12 
(5), INC. d 
131 ± 3 
( 6), INC. 
159 ± 15 
( 6), INC. 
165 :t 21 
(4), INC. 
164 ± 19 
(4), INC. 
184 ± 2 
( 2), INC. 
PARGYLINE 
115 ± 8 
(5), N.S. 
86 ± 19 
( 6), DEC, d 
94 ± 13 
(6) I DEC. 
90 ± 8 
( 6), DEC. 
89 ± 9 
(6), !EC. 
83 ± 10 
( 6), DEC. 
a: mean systolic blood pressure ± S.D. 
b: number of rats. 
120 :!: 12 
(6), N.S. 
112 :t 3 
(6), N.S. 
114 !' 9 
(6), N.S. 
109 ± 6 
(6), N.S. 
COMBINED 
118 :t 15 
(4), N.S. 
c: mean systolic blood pressure ± S.D. of all four groups 
d: at P ~ 0.05: 
116 ± 10 
( 23) 
119 ± 8 
(24) 
116 :t 9 
( 24) 
114 !' 18 
( 24) 
N.S. =not significantly different from group I (or vehicle). 
INC. = significantly elevated over vehicle-treated group. 
DEC. = significantly decreased from vehicle-treated group. 
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Drug~. Daily~ Day _Q: &, Thyroxine, 1 mg/kg; Pargyline .HQJ., 25 mg/kg; 
Combined, Na thyroxine, 1 mg/kg + pargyline HCl, 25 mg/kg; Vehicle, glass-
distilled water, l ml/kg. All injected i.p. 
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FIG. 1. TiiE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON MEAN 
SYSTOLIC BLOOD PRESSURE IN MAIE ALBINO RATS 
(Principal Blood Pressure Study) 
Solid symbols designate significant 
difference (P ~ 0.05) from controls. 
Thyroxine ( ~) 
~121~ 
I 
100 
80w 
-12 
All Rats 
Before Treatment 
:...a 
-4 0 
Pargyline ( O) 
4 8 12 16 20 
_Day of Treatment 
Doses (i.p.) daily from day O: Na Thyroxine, 1 mg/kg. Pargyline HCl, 25 mg/kg. 
Combined, Na thyroxine and pargyline HCl as above. Control, glass-distilled water, 
l ~g/kg. 
~ 
\JI 
TABIE 2 
SUPPIEMENTARY BLOOD PRESSURE STUDY : THE EFFECTS OF CHRONIC COMBINED 
THYROXINE AND PARGYLINE TREATMENT ON SYSTOLIC BLOOD PRESSURE IN MALE 
ALBINO RATS 
DAY I II POOLED 
121 + 13a 112 :!: 10 116 :t 
-
-6 
( 6)b (6), N.S. d (12) 
113 + 7 108 ! 6 111 :!: 
-
-4 
( 6) (6), N.S. 02) 
Daily Drug Injection Began 2.!! Day _Q. 
VEHICIE COMBINED 
3 113 :!: 6 100 :!: 3 
( 6) (3), N. S. 
a: mean systolic blood pressure + S.D. 
b: number of rats. 
c 
2 
2 
c: mean systolic blood pressure + S.D. of both groups. 
d: at P s; 0.05 : 
N.S. = not significantly different from group I 
(or vehicle). 
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Drug Doses, Daily!!:.£!!! Daz .Q: ~Thyroxine, 1 mg/kg, + Pargyline 
HCl, 25 mg/kg ; Vehicle , glass-distilled water, 1 ml/kg. All 
injected i. p. 
TABLE 3 
THE EFFE CTS OF CHRONIC THYROXINE AND PARGYLINE TREA1MENT ON URINARY 
SODIUM EXCRET ION IN MAIE ALBINO RATS 
DAY 
1 
2 
3 
4 
5 
6 
7 
8 
10 
VEHICLE THYROXINE 
2.38 ! o . soa 3 . 02 ! o . 61 
(4)b (4) , N.S . 
2 . 66 :t 0 . 53 
( 4) 
2.80 + 0.66 
(4 ) 
2.38 + 0 .60 
(3) 
2 .88 ± 1.26 
( 3) 
2. 76 ± 1.48 
( 7) 
3 .05 ± 0.84 
( 4) 
3.18 ± 0 . 68 
( 5) 
3 . 15 ± 1.06 
( 5) 
3 '10 ± 0.72 
( 4.), N.S. 
2.20 :t 0.91 
(3), N. S . 
4.11 ± 1.45 
(2), N.S. 
5 . 67 ± 1. 28 
( 5), INC. 
5 . 00 ± 0.95 
( 6) , INC. 
3.90 ± o.77 
(5), N.S. 
4 .74 ± 0 . 74 
(4 ) • INC. 
PARGYLINE 
2.01 :t 0.44 
(4), N.S. 
1 '15 ± 0 .58 
(4) , N . S. 
2.29 ± 0.99 
(3), N.S. 
2.16 .± 0.91 
(3), N.S. 
2.75 :± 0.70 
(4), N.S. 
2 . 82 ± 1.12 
( 3 ) , N.S. 
2. 37 ± 0.59 
(4) , N . S . 
2.14 :± 0 . 57 
(3), N. S . 
2.12 :t 0 . 05 
(3) , N. S. 
a : mean, z S.D., nlEq Na•/cage of 3 rats/day. 
b : number of cages . 
c: at P ~ 0 . 05 : 
COMBINED 
3 . 53 ! 0.77 
(12), INC.c 
3.48 ± 0.97 
(8), N.S. 
2.92 ± 0 . 66 
(9) , N.S. 
3.18 .± 0.28 
(5), N.S. 
3.54 ± 0.67 
(7), N.S. 
5.10 + .?.21 
(7), N.S. 
3.75 ± 0.45 
(5), N . S . 
3 , 07 :± 1.48 
(3), N . S. 
N. S . = not significantly different from vehicle- treated group. 
INC. = s i gnif icant ly eleva te d over vehic le- treated group. 
Drug Doses , Daily, From Day .Q: Na Thyroxine, 1 mg/kg , days 0-4; 
0.5 mg/kg, days 5~10. Pargyl ine .!!.£!, 25 mg/kg. Combined. thyroxine as 
above + pargyl i ne , as above. Vehicle , glass-d i stilled water, 1 ml/kg. 
All injected i.p. 
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FIG. 2, THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON 
MEAN URINARY SODIUM EXCRETION IN MALE ALBINO RATS 
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Solid symbols designate 
significant difference 
(P ~ 0.05) from controls. 
4 6 
Day ~ Treatment 
Thyroxine ( D. ) 
Combined ( 0) 
Control ( 0) 
Pargyline (O) 
8 0 
Doses (i.p.) daily from day 0: !!! Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5-10. Pargyline HCl, 25 mg/kg. Combined, Na thyroxine and 
pargyline HCl as above. Control , glass-distilled water, 1 ml/kg. 
TABLE 4 
TIIE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON URINARY 
POTASSIUM EXCRETION IN MAIE ALBINO RATS 
1 
2 
3 
4 
5 
6 
7 
8 
10 
VEHICIE THYROXINE 
4.98 ± 0.85a 5.47 + 1.05 
(4)b (4), N.s.c 
5.70 ± 0.91 
( 4) 
5.36 ± 0.70 
(4) 
5.34 ± 1.34 
(3) 
6.12 ± 2.70 
( 3) 
5.53 + 2.70 
( 7) 
6.58 ± 1.01 
( 4) 
6.74 ± o.95 
( 5) 
6.41 ± 1.45 
( 5) 
6. 04 ± 1. 66 
(4), N.S. 
5.66 ! 2.49 
(3), N.S. 
7. 32 .± 1. 75 
(2), N.S. 
10.75 ± 2.54 
( 5), INC. 
9.81 ± 1.15 
( 6), INC. 
8.42 ± 0.89 
( 5), INC. 
9.39 ± 1 . • 21 
(4) , INC. 
PARGYLINE 
4.50 ± 0.99 
(4), N.S. 
4.67 ± 0.97 
(4), N.S. 
4.94 :!: 1. 97 
(3), N.S. 
4.74 ± 1.96 
(3), N.S. 
5,35 ± 1.16 
(4), N.S. 
5.73 :t 1.80 
(3), N.S. 
5.70 !' 0.86 
(4), N.S. 
5.13 .:t 0.81 
(3), me. 
4.74 .t 0.32 
(3), N.S. 
+ 
a: means ± S .D., mEq K /cage of 3 rats/day. 
b: number of cages. 
c: at P $ 0.05: 
COMBINED 
6. 73 :t 1.32 
( 12), INC. 
7 .13 :t 0. 96 
( 8), INC. 
6,17 ± 0.94 
(9), N.S. 
6.03 ± 0,19 
(5), N.S. 
7.07 :t 0.84 
(7), N.S. 
8.83 ± 3.19 
(7), N.S. 
7.95 ± 0.63 
(5), N.S. 
5.97 :!: 2.64 
(3), N.S. 
N.S . = not significantly different from vehicle-treated group. 
INC. = significantly elevated over vehicle-treated group. 
DEC. = significantly decreased from vehicle-treated group. 
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Drug Doses, Daily, From Day Q: Na Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5-10. Pargyline HCl, 25 mg?kg. Combined, thyroxine as above + pargy-
line, as above. Vehicle, glass-distilled water, l ml/kg. All injected i.p. 
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FIG. 3. THE EFFECTS OF CHRONIC THYROXINE AND PARGYLING TREA'IMENT 
ON MEAN URINARY POTASSIUM EXCRETION IN MAIB ALBINO RATS 
0 
Solid symbols designate 
significant difference 
(P $. 0.05) from controls. 
6 
Day of Treatment 
<o) 
Pargyline <O) 
8 10 
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~ (i.p.) daily from day 0: !!_Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5-10. Pargyline !!£!., 25 mg/kg. Combined, Na thyroxine and 
pargyline HCl as above. Control, glass-distilled water, 1 ml / kg. 
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TABLE 5 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON THE WEIGHT 
GAINS OF MAIE ALBINO RATS: I. DAILY WEIGHTS 
DAY VEHICLE THYROXINE PARGYLINE COMBINED 
0 209 :t 218 213 = 17 230 :t 21 231 ± 13 
( 6) b (6), N.S.c (6), N.S. (6), N.S. 
1 212 + 211 ! 13 233 ± 18 227 :! 13 
-( 6) (6), N.S. (6), N.S. (6), N.S . 
2 213 + 21 210 :! 16 230 ± 19 227 ± 13 
( 6) (6), N.S. (6), N.S . (6), N.S. 
3 215 :t 24 206 ± 20 231 :! 20 233 ± 16 
( 6) (6), N.S. ( 6)' }.. . :i. (5), N.S. 
4 218 :t 24 202 .± 18 230 .± 19 225 ± 12 
( 6) (6), N.S . (6), N.S . (5), N.S. 
5 222 :! 26 201 ! 18 230 .± 20 220 ± 14 
( 6) (6), N.S. (6), N.S. (5), N.S. 
6 228 :! 26 201 :t 19 237 :!: 22 224 :t 14 
( 6) (6), N.S. (6), N.S. (5), N.S. 
7 227 ! 27 190 :t 19 234 ! 20 220 .± 19 
( 6) (6), IEC. (6), N.S . (4), N.S. 
8 232 :t 31 192 :t 19 239 ± 22 229 ± 16 
( 6) (6), IEC. (6), N.S. (2), N.S. 
9 237 :t 30 188 :t 23 245 ! 21 228 .± 14 
( 6) (6), DEC. (6), N.S. (2), N.S. 
10 235 + 29 179 .± 23 240 :! 21 216 ! 14 
-( 6) (6), IEC. (6), N.S . (2), N.S. 
11 241 + 32 193 :t 18 248 .± 24 
( 6) (4), DEC. (6), N.S . 
12 241 + 30 183 ± 25 248 :t 24 
( 6) (4), DEC . (6), N.S. 
13 244 ± 32 182 !' 21 250 :! 27 
( 6) (4), DEC. (6), N.S. 
14 255 + 
-
33 182 !' 22 258 :!: 27 
(6) (4), IEC. (6), N.S. 
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Table 5 (Continued) 
DAY VEHICIE THYROXINE PARGYLINE COMBINED 
15 260 :!: 37 184 ± 20 265 ± 29 
( 6) (4), DEC. (6), N.S. 
16 256 ± 36 175 .: 22 267 :!: 32 
( 6) (4), IEC. (6), N.S. 
17 257 ± 38 168 ± 15 268 :!: 34 
(6) (3), DEC . (6), N.S. 
18 272 + 37 179 ± 26 274 :t 36 
( 6) (3), IEC. (6), N.S . 
19 270 + 37 169 :!: 25 276 :t 35 
( 6) (3), DEC. (6), N.S. 
20 261 + 34 171 :!: 31 274 ± 33 
(6) (2), IEC. (6) , N.S. 
21 266 :t 18 167 ± 38 279 ! 37 
( 5) (2), DEC. (6), N.S. 
22 270 + 26 282 ± 35 
( 5) (6), N.S . 
23 262 ± 25 285 .: 38 
(4) (6), N.S. 
24 274 + 36 286 ± 36 
(4) (6), N.S. 
25 271 + 34 290 ± 40 
(4) (6), N.S. 
26 278 ± 35 302 ± 39 
(4) (6), N.S. 
a: mean, :!: S .D., daily weights . 
b: number of rats. 
c: at P ~ 0.05: 
N.S. = not significantly different from vehicle-treated group. 
DEC. = significantly decreased from vehicle-treated group. 
Drug~. Daily, ~Day£: ~Thyroxine, 1 mg/kg, days 0-19; 0.5 mg/kg, 
days 20-21. Pargyline !!£!., 25 mg/kg. Combined, thyroxine as above + pargy-
line as above. Vehicle, glass- distilled water, 1 ml/kg. All injected i.p. 
These animals form the principal group of phase 1 (see Page 28, Summary of 
Experimental Design). 
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FIG. 4. TilE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT 
ON THE WEIGHT GAINS OF MALE ALBINO RATS. I. MEAN DAILY 
WEIGHTS. 
Solid symbols designate 
300 significant difference 
(P ~ 0.05) from controls. 
280 Pargyline ( D ) 
260 
53 
s 240 
Combined ( 0 ) 
220 
200 
Thyroxine ( 6) 
180 
Day of Treatment 
Doses (i.p.) daily from day O: ~Thyroxine, 1 mg/kg, days 0-19; o.5 mg/kg, 
days 20-21. Pargyline HCl, 25 mg/kg. Combined, Na thyroxine and 
pargyline HCl as above.--Control, glass-distilled water, 1 ml/kg. 
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TAB IE 6 
TIIE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON THE WEIGHT GA INS 
OF MAIE ALBINO RATS: II. CUMULATIVE DAILY WEIGHT GAINS FROM DAY 0 
DAY VEHICIE THYROXINE PARGYLINE COMBINED 
1 3 ± 68 -2 ± 7 3 ± 7 
-4 :!: 5 
( 6)b (6), N.S. c (6), N.S . ( 6), DEC. c 
2 4 ± 2 -3 ! 6 0 ± 6 -4 ± 6 
( 6) ( 6), DEC. (6), N.S. (6), DEC. 
3 6 ± 5 -7 .t 5 1 ± 6 
-3 :!: 19 
( 6) ( 6), DEC. ( 6), DEC. (5), N.S. 
4 9 ± 3 -11 ± 5 1 .± 6 
-3 ± 19 
( 6) ( 6), IEC. ( 6), DEC. ( 5), DEC. 
5 13 ! 5 -12 ± 3 0 ± 5 
-16 ± 17 
( 6) (6), IEC. ( 6), DEC. ( 5), DEC. 
6 20 ± 7 -12 .± 4 7 .± 8 
-12 ± 19 
( 6) (6), DEC. (6), DEC. ( 5), DEC . 
7 18 .t 7 
-23 ± 7 4 ± 5 _13 ± 15 
( 6) ( 6), DEC. (6), DEC. (4), DEC. 
8 23 ± 11 -21 ± 7 9 ± 7 
-7 ± 9 ( 6) ( 6), DEC. (6), DEC. (2), IEC. 
9 28 ± 11 
-25 ± 13 14 ± 5 -7 ± 7 (6) ( 6), DEC. ( 6), DEC. ( 2), IEC . 
10 27 ± 6 
-34 ± 15 9 ± 6 
-19 ± 7 ( 6) ( 6), me. (6), DEC. (2), DEC. 
11 32 :!: 12 
-18 ± 4 18 .t 10 ( 6) (4), DEC. (6), DEC. 
12 32 .± 11 
-29 ± 5 18 .t 7 ( 6) (4), DEC. ( 6), DEC. 
13 35 ± 12 
-30 :t 6 20 :!: 11 ( 6) (4), DEC. ( 6), DEC . 
14 46 :!: 14 
-30 :! 8 28 :!: 11 ( 6) (4), IEC. ( 6), DEC. 
15 51 ! 17 
-27 :!: 9 34 : 14 ( 6) (4), DEC. (6), N.S. 
Table 6 (Continued) 
DAY VEHICLE THYROXINE PARGYLINE COMBINED 
16 47 :!: 16 -37 ! 11 37 ± 16 
( 6) (4), DEC. ( 6)' N.S . 
17 47 :!: 19 -51 ! 8 37 :!: 18 
( 6) (3)' DEC. (6), N.S. 
18 63 :!: 18 -40 ! 8 44 ! 21 
( 6) ( 3)' DEC. (6), N.S. 
19 61 ! 17 -49 ! 8 46 :!: 19 
( 6) (3). DEC. (6), N.S. 
20 52 ! 16 -53 ! 7 44 ! 17 
( 6) ( 2)' DEC. (6), N.S. 
21 64 ! 18 -58 ! 13 49 :!: 21 
( 5) (2), DEC. (6), N.S. 
22 68 ! 24 51 :!: 19 
( 5) (6), N.S. 
23 65 ! 17 55 :!: 23 
(4) ( 6)' N.S. 
24 77 : 27 56 ± 20 
( 4) ( 6). N.S. 
25 74 :!: 24 60 :!: 24 
(4) ( 6)' N.S. 
26 81 :!: 26 72 :t 23 
(4) ( 6). N. S. 
a: mean, + S .D., cumulative weight gains from day o. 
-
b : 
c: 
number of rats. 
at P S 0.05: 
N.S. = not significantly different from vehicle-treated group. 
DEC. = significantly decreased from vehicle-treated group. 
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Drug Doses, Daily, ~ Day~: ~ Thyroxine, 1 mg/kg, days 0-19; 0.5 m~/kg, 
days 20-21. Pargyline '!!21· 25 mg/kg. Combined , thyroxine as abov~ + pargy-
line as above. Vehicle, glass-distilled water, 1 ml/kg. All injected i.p. 
These animals form the principal group of phase 1 (see Page 28, Summary of 
Experimental Design). 
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FIG. 5. THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT 
ON THE WEIGHT GAINS OF MALE ALBINO RATS. II. MEAN 
CUMULATIVE WEIGHT GAINS FROM DAY O. 
Solid symbols des i gnate 
80 significant difference 
(P ~ 0.05) from controls . 
60 
Control 
Pargyline ( 0) 
40 
56 
m 20 
s 
0 
-20 
Thyroxine ( 6.) 
- 60 0 4 8 12 
Day of Treatment 
Doses (i.p.) daily from day 0 : ~Thyroxine, 1 mg/kg , days 0-19; 0.5 mg/kg, 
days 20=21. Pargyline HCl , 25 mg/kg. Combined, Na thyroxine and 
pargyline HCl as above. Control, glass- distilled water, 1 ml/kg. 
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TABI.E 7 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON THE WEIGHT GAINS 
OF MAIE ALBINO RATS: III. DAILY WEIGHT GAINS 
DAY 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
VEHICLE 
1 :!: 4 
( 6) 
2 ± 5 
( 6) 
3 : 6 
( 6) 
4 ± 4 
(6) 
6 ± 5 
( 6) 
-1 :!: 6 
( 6) 
5 :!: 5 
( 6) 
5 .± 6 
( 6) 
-2 :t: 3 
( 6) 
5 ± 5 
( 6) 
0 .± 3 
( 6) 
3 :!:: 4 
( 6) 
11 .± 5 
( 6) 
5 ± 5 
( 6) 
THYROXINE 
-2 ! 7 
c (6), N.S. 
-1 :!:: 5 
(6), N.S. 
-4 ± 6 
(6), N.S. 
-4 :!: 3 
(6), me. 
-1 ~ 3 
(6), DEC. 
0 .± 2 
(6), DEC. 
-10 ± 5 
( 6), DEC. 
2 :!: 5 
(6), N.S. 
-5 ± 7 
(6), DEC. 
-8 ± 4 
(6), me. 
9 ± 12 
(4), N.S. 
-11 .:t 6 
(4), DEC. 
-1 ± 1 
(4), N.S. 
-1 .± 3 
(4), DEC. 
3 ± 3 
(4), N.S. 
PARGYLINE 
3 ! 3 
(6), N.S. 
-3 : 5 
(6), N.S. 
1 ± 2 
(6), N.S. 
-1 ± 4 
(6), N.S. 
0 ± 5 
(6), N.S. 
7 ± 4 
(6), N.S. 
-3 ± 6 
(6), N.S. 
5 ± 3 
(6), N.S. 
6 ± 5 
(6), N.S. 
-5 ± 3 
(6), N.S. 
8 ± 7 
(6), N.S. 
1 ± 6 
(6), N.S. 
2 .:t 5 
(6), N.S. 
8 :!:: 4 
(6), N.S. 
6 ± 5 
(6), N.S. 
COMBINED 
-4 :!: 5 
(6), DEC. 
0 :!: 4 
(6), N.S. 
2 ± 13 
(5), N.S. 
-9 ± 9 
(5), N.S. 
-5 .:t 5 
(5), me. 
4 .± 6 
(5), N . S. 
-9 ± 12 
(4), N.S. 
-7 :!: 5 
(2), N.S. 
-1 ± 2 
( 2), DEC. 
-12 :!: 0 
( 2), DEC . 
Table 7 (Continued) 
DAY 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
a : 
b: 
c: 
VEHICLE THYROXI NE PARGYLINE COMB I NED 
-4 ~ 3 - 9 ! 5 2 ± 3 
( 6) (4), N.S. ( 6), INC . 
2 ± 4 -10 ± 12 1 ! 4 
( 6) (3) I N.S. (6), N.S. 
14 ± 2 11 : 11 7 ! 3 
( 6) (3) I N.S. ( 6), DEC. 
-2 ± 3 -20 :!: 2 2 .± 3 
( 6) (3) I IEC. (6), N.S. 
-9 ± 14 -8 ± 6 -2 ± 4 
(6) (2), N.S. ( 6), N.S. 
18 :!: 21 -5 :!: 6 5 .± 5 
( 5) (2), N. S. (6), N.S. 
4 :!: 15 3 ~ 5 
( 5) (6), N.S. 
-11 + 8 3 :!: 6 
(4) ( 6) I INC. 
12 ± 14 1 : 6 
(4) (6), N.S. 
-3 ! 13 4 ± 5 
(4) (6), N.S. 
7 .± 3 12 ! 3 
(4) ( 6)' INC. 
mean, ± S .D., daily weight gains. 
number of rats. 
at p .$ 0.05: 
N.S. =not significantly different from vehicle-treated group. 
INC. = significantly elevated over vehic le-treated group. 
DEC. = significantly decreased from vehicle- trea t ed group. 
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Drug Doses , Daily , ~ Day£: ~ Thyroxine, 1 mg/kg, days 0-19; 0,5 mg/kg, 
days 20-21. Pargyline HCl, 25 mg/kg. Combined , thyroxine as above + pargy-
line as above. Vehicle, glass-distilled water, 1 ml/kg. All injected i.p. 
These animals form the principal group of phase 1 (see Page 28 , Summary of 
Experimental Design). 
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TABLE 8 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON THE WEIGHT GAINS 
OF MALE ALBINO RATS : CUMULATIVE DAILY WEIGHT GAINS FROM DAY 0 
DAY VEHICLE THYROXINE PARGYLINE 
1 5 :t 5a -3 ! 10 1 .t 7 
( 26)b (15) , DEC. c (15)' N.S. 
2 11 :!: 9 -13 ± 14 2 :!: 12 
(15) (15)' DEC. (15), DEC. 
3 9 ± 13 -5 :± 17 4 ! 15 
( 25) (12)' rnc. (11), N.S. 
4 17 :!: 12 -1 ± 8 7 ± 8 
( 11) (10), IEC. (10)' DEC. 
5 13 :t 15 1 .t 10 13 :t 14 
( 20) (9), DEC. (10), N.S. 
6 19 .± 11 4 ± 21 19 :t 9 
(15) (7), N.S. (10), N.S. 
7 29 ± 12 3 :!: 21 23 ± 8 
(13) ( 6), DEC. (10), N.S. 
8 29 ± 9 - 5 :!: 22 25 :!: 8 
( 11) (6), DEC. (10), N.S. 
9 32 :!: 11 3 ! 22 35 :!: 9 
(12) ( 6) ' IEC. (10), N.S. 
10 37 ± 15 1 ± 18 36 ± 7 
(12) (6) , DEC. (10), N.S. 
11 44 :!: 11 1 :t 20 43 .t 7 
(12) ( 6)' IEC. (10), N.S. 
a : mean, ± S . D., cumulative weight gains from day 0. 
b: number of rats. 
c : at P ~ 0.05 : 
COMBINED 
-1 ± 5 
(39), DEC. 
-3 .t 10 
(39), DEC. 
-5 ± 9 
( 30)' IEC. 
-13 ± 13 
(30)' DEC. 
-12 ± 13 
(20), DEC. 
-12 ± 16 
(21), DEC. 
-11 :t 9 
(15)' IEC. 
-17 ! 11 
(12). rnc. 
-14 :!: 9 
(6), DEC. 
-10 :!: 9 
(4), IEC. 
-15 :!: 13 
( 4)' DEC. 
N. S. = not significantly different from vehicle-treated group . 
. DEC . = significantly decreased from vehicle-treated groups. 
Drug~. Daily, ~Day _Q : ~Thyroxine, 1 mg/kg, days 0- 4; 0.5 mg/kg, 
days 5-11. Pargyline HCl , 25 mg/kg. Combined, thyroxine as above + pargy-
line as above. Vehicle, glass-distilled water, 1 ml/kg. All injected i.p. 
These animals form the principal group of phase 2 (see Page 28, Summary of 
Experimental Design). 
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FIG. 6. TilE EFFECTS OF CHRONIC TIIYROXI NE AND PARGYLINE TREATMENT 
ON THE WEIGHT GAINS OF MALE AlBINO RATS. MEAN CUMULATIVE 
WEIGHT GAINS FROM DAY O. 
Solid symbols designate 
significant difference 
40 (P ~ 0.05) from controls. 
30 
Control ( 0) 
Pargyline ( 0) 
20 
60 
s 10 
0 
-10 Combined ( <> ) 
-20~~~~..__~....._~_..,~~--~ ......... ~~~--'~~--~~~--'~---' 
0 2 4 6 8 10 
Day~ Treatment \ 
Doses (i.p.) daily from day O: !'!!Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5- 11 . Pargyline .!!£.! , 25 mg/kg. Combined, Na thyroxine and 
pargyline HCl as above. Control, glass-distilled water, 1 ml/kg. 
TABI.E 9 
PARTIAL PURIFICATION OF MONOAMINE OXIDASE FROM BRAIN AND LIVER OF MALE 
ALBINO RATS 
PREPARATION MAO ACTIVIT"Y8 , ~mol kynuramine/hr/mg protein at 29°c 
BRAIN LIVER 
--
Homogenate 0.39 1. 78 
Mitochondria 0. 78 2.72 
3 Increase 200 150 
a : Assayed as described in Methods section, Page 39. 
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TABLE 10 
STABILITY STUDY : MONOAMINE OXIDASE ACTIVITY IN BRAIN AND LIVER OF MALE 
ALBINO RATS, MITOCHONDRIA STORED AT -40°C 
DAYS IN FREEZER at -4o0c 
a MAO ACTIVITY , pmol kynuramine/hr/mg protein, 
at 3o0 cb 
BRAIN LIVER 
0 (fresh) 0.62 2.93 
2 0.63 
4 2.97 
7 0.67 
9 0.63 
15 0,65 
85 3.41 
101 0.62 
a: Mitochondria were assayed as described in Methods section, Page 39. 
b: The se assays were carried out at ambient room temperatures, 24.4-30°C. 
MAO activity was found to increase 0.0143 pmol kynuramine/hr/mg pro-
tein/0C in brain and 0.192 pmol kynuramine/hr/mg protein/OC in liver. 
Reported values are corrected for 3ooc. 
TABLE 11 
TERMINAL BRAIN MONOAMI NE OXIDASE ACTIVI TY IN MALE ALBINO RATS 
RAT 
NUMBER 
PROTEIN IN 
MITOCHONDRIAL 
SUSPENSION, mg/ml 
PROTEIN IN 
MAO ASSAY 
CUVETTE, mg 
TERMINAL 
MAO ACTIVITY, 
pmol kynuramine/ 
hr/mg protein 
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1. DRUG TREATMENT: VEHICLE (glass-distilled water). 1 ml/kg, i.p., daily, 
days 0-11. 
3-1-br 
3-3- br 
4- 2-br 
4-3-br 
1.84 
1. 73 
1.67 
1.47 
2.76 
2.60 
2.51 
2.21 
0.61 
0.69 
0.69 
0.84 
2. DRUG TREATMENT: VEHICLE. 1 ml/kg, i.p., daily, days 0-17. 
S-2v2-br 
S-2v3-br 
0.96 
1.28 
1.44 
1.92 
1.36 
0.80 
3. DRUG TREATMENT: VEHICLE. 1 ml/kg, i.p., daily, days 0-27. 
W-3-br 
W-4-br 
W-5-br 
1.65 
1.29 
1.50 
2.48 
1 Q4 
2.25 
0.61 
0.95 
0.92 
4. DRUG TREATMENT: Na THYROXINE. 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-11. 
5. 
6. 
i.p. daily 
18-1-br 
18-2-br 
18-3-br 
DRUG TREATMENT: 
i.p. daily 
T-2-br 
DRUG TREATMENT: 
9-2-br 
10-1-br 
10- 2-br 
10-3-br 
11-la- br 
11-lb-br 
11-3-br 
12-1-br 
12-2-br 
12-3-br 
19-1-br 
19-2-br 
19-3-br 
1.43 
1.47 
1.43 
Na THYROXINE. 
1.50 
PARGYLINE RC 1 . 
1.43 
1. 79 
1.29 
0 . 73 
0 . 84 
2.61 
0.85 
1. 50 
1.45 
1.28 
1.20 
1.39 
1.39 
2.15 
2.21 
2.15 
0.84 
0.66 
0.65 
1 mg/kg, days 0-19; 0.5 mg/kg, days 20-28. 
2 . 25 0 . 83 
25 mg/kg, i . p., daily, days 0-11. 
2.15 
2.69 
1.94 
1.10 
1.26 
3.92 
1.28 
2.25 
2.18 
1.92 
1.80 
2.09 
2.09 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Table 11 (Continued) 
RAT 
NUMBER 
PROTEIN IN 
MITOCHONDRIAL 
SUSPENSION. mg/ml 
PROTEIN IN 
MAO ASSAY 
CUVETTE, mg 
TERMINAL 
MAO ACTIVITY, 
pmol kynuramine/ 
hr /mg protein 
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7. DRUG TREATMENT: PARGYLINE HCl. 25 mg/kg, i.p., daily, days 0-27. 
M-1-br 1. 78 2.67 0 
M-2-br 1.19 1. 79 0 
M-3-br 1.60 2.40 0 
M-4-br 1.17 1. 76 0 
M-5-br 1.28 1.92 0 
M-6-br 1.18 1. 77 0 
8. DRUG TREATMENT: Na THYROXINE . 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-11. 
+ PARGYLINE RC 1 , 25 mg/kg, days 0-11, i. p. daily. 
20-1-br 1. 77 2.66 0 
20-3-br 1.39 2.09 0 
20-4-br 2.13 3.22 0 
9. DRUG TREATMENT: Na THYROXINE • 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-9. 
+ PARGYLINE !!£!, 25 mg/kg, days 0-9, i.p. daily. 
S-17c3-br 1.11 1.67 0 
S-18c2~br 0.89 1.34 0 
S-19cl-br 1.37 2.06 0 
S-19c3-br 0.96 1.44 0 
MAO assay described in Methods section, Page 39. 
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TABLE 12 
TERMINAL LIVER MONOAMINE OXIDASE ACTIVITY IN MALE ALBINO RATS 
'IERMINAL 
PRO'IEIN IN PROTEIN IN MAO ACTIVITY, 
RAT MITOCHONDRIAL MAO ASSAY }.llllOl kynuramine/ 
NUMBER SUSPENSION 1 mg/ml CUVETTE, mg hr /mg prate in 
1. DRUG TREATMENT: VEHICLE (glass-distilled water). 1 ml/kg, i.p. daily, 
days 0-11. 
3-1-L 14.15 1.42 3.33 
3-3-L 4.45 0.45 3.56 
4-2-L 9.90 0.99 1.54 
4-3- L 5.40 0.54 2.97 
2. DRUG TREA'IMENT: VEHICIB. 1 ml/kg, i.p. daily, days 0-17. 
S-2v2-L 2.29 0.46 2.10 
S-2v3-L 1.87 0.19 4.06 
3. DRUG TREATMENT: VEHICLE. 1 ml/kg, i.p. daily, days 0-27. 
W-2-L 1. 53 0.15 3.29 
W-3-L 2.08 0.62 2.49 
W-4-L 2.65 1.33 2.43 
4. DRUG TREATMENT: Na THYROXINE . 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-11. 
i.p. daily 
18-1-L 6.60 0.66 2.43 
18-2-L 3 . 35 0.34 2.54 
18-3- L 8.20 0.82 1.55 
5. DRUG TREA 'IMENT: Na TIIYROXINE • 1 mg/kg, days 0-19; 0 . 5 mg/kg, days 20-28. 
i.p. daily 
T-2-L 2.18 1.09 1.04 
6. DRUG TREA'IMENT: PARGYLINE HCl. 25 mg/kg, i.p. daily, days 0-11. 
9-2-L 2.00 0.20 0 
10-1-L 1.36 0.14 0 
10-2- L 3.90 0.39 0 
10-3-L 7.45 0.75 0 
11-la-L 10.00 0.10 0 
11-lb-L 6.85 0.69 0 
11-3- L 7.00 0 .70 0 
12-1-L 5.50 0.55 0 
12-2-L 6.ln 0.61 0 
12-3-L 7 . 45 n. 75 0 
19- 1-L 2.06 2.06 0 
19-2-L 1.65 0.17 0 
19-3-L 1.94 0.19 0 
Table 12 (Continued) 
RAT 
NUMBER 
PROTEIN IN 
MITOCHONDRIAL 
SUSPENSION, mg/ml 
PROTEIN IN 
MAO ASSAY 
CUVETTE, mg 
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TERMINAL 
MAO ACTIVITY, 
pmol kynuramine/ 
hr /mg protein 
7. DRUG TREATMENT: PARGYLINE HCl. 25 mg/kg, i.p. daily, days 0-27. 
M-1-L 1.49 0.15 0 
M-2-L 1. 93 0.19 0 
M-~-L 3 . 50 0 . 35 0 
M-4-L 3 . 50 0.35 0 
M-5-L 1.53 0.15 0 
M-6-L 2.65 0.27 0 
8. DRUG TREATMENT: Na THYROXINE. 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-11. 
+ PARGYLINE !!£!., 25 mg/kg , days 0-11, i.p. daily. 
20-1-L 
20-3-L 
20-4-L 
2.65 
3.95 
1.85 
0.27 
0.40 
0.19 
0 
0 
0 
9. DRUG TREATMENT: Na THYROXINE. 1 mg/kg, days 0-4; 0.5 mg/kg, days 5-9. 
+ PARGYLINE HCl, 25 mg/kg, days 0-9, i.p. daily. 
S-17c3-L 
S-18c2-L 
S-19cl-L 
S-19c3-L 
1.87 
1.45 
1.58 
1.87 
0 .19 
0.15 
0 .16 
0.19 
MAO assay described in Methods section, Page 39. 
0 
0 
0 
0 
,. 
TABIE 13 
SUMMARY OF TABIES 11 AND 12 
TERMINAL MONOAMINE OXIDASE ACTIVITY IN MAIE ALBINO RATS 
TISSUE 
Brain 
· a 
N 
X .± S. D.b 
Liver 
N 
X ~ S .D. 
c Group 1 
Vehicle-
treated 
4 
0.71 
4 
a 
+ 0. 11. 0 
2.85 :.!: 0.91 
a: N = number of rats . 
Groups 1, 2,&3 
All Vehicle-
treated 
9 
0.83 ± 0.24 
9 
2 . 86 :.!: 0.79 
DRUG TREA'IMENT GROUP 
Group 4 
Thyroxine-
trea ted 
3 
0.72 ± 0.11 
3 
2.17 ± 0.77 
Groups 6&7 
Pargyline-
treated 
19 
0 
19 
0 
Groups 8&9 
Combined Thyroxine 
+ Pargyline-treated 
7 
0 
7 
0 
b: Indicates mean ! S.D. of MAO activi ty i n units of pmol kynuramine/hr/mg protein, at 3o0 c . 
c : Groups are the drug-treatment groups of Tables ..!:..!. and 12. 
TISSUE 
Brain 
Brain 
Liver 
Liver 
STATISTICAL COMPARISONS 
COMPARISONd 
Group 1 , Vehicle , vs . Group 4, Thyroxine. 
Groups 1,2,&3 , All Vehicles, vs . Group 4 , Thyroxine . 
Group 1, Vehicle , vs. Group 4, Thyroxine. 
Groups 1,2,&3, All Vehicles, vs. Group 4, Thyroxine. 
RESULT 
d 
N.S. 
N. S. 
N. S. 
N.S. 
d: Comparisons were made by means of Student ' s "t" test (Snedecor, 1956). N. S. =no significant 
difference, P s 0.05. 
O'I 
"' 
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TABIE 14 
PRELIMINARY STUDY: ACTOPHOTOMETRIC METHOD FOR MEASURING GROSS ACTIVITY IN 
MALE ALBINO RATS 
TYPICAL DATA GENERATED BY TWO UNTREATED GROUPS OF RATS RUN IN THE ACTOPHOTO-
METER FOR 6 HOURS. INCREMENTAL COUNTS PER 30 MINUTES. 
DA TA FROM CAGE I LENGTH OF STUDY: 12 DAYS 
TIME (hr) GROUP 1 (odd days) GROUP 2 (even days) COMPARISON 
x S.D. C(3) x S·.O. C(3) group 1 vs. group 2 
! 1241 296 24 1030 223 22 N.S. 
1 553 346 63 336 137 41 N.S. 
l .l 2 125 161 128 91 121 133 N.S. 
2 7 10 140 9 13 156 N.S. 
2! 16 27 174 36 78 215 N.S. 
3 14 9 62 20 40 202 N.S. 
3.l 2 9 9 101 45 43 96 N.S. 
4 26 28 107 80 116 145 N.S. 
4! 211 240 114 72 77 107 N.S. 
5 127 180 142 156 245 157 N.S. 
5! 130 182 111 144 171 94 IJ . ~. 
6 447 238 53 161 158 98 SIGN. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, S.D./X x 1003 . 
The mean ! S.D. of counts generated during each of the 12 half-hour 
periods by group 1, three rats run in the cage on the odd days (days 1,3, 
5,7,9,11) was computed. Each of the 12 means! S.D. w~compared to the 
mean ± S . D. of counts generated during the same half-hour interval by 
group 2, three rats run in the cage on the~ days (days 2,4,6,8,10,12). 
Comparisons were made by means of Student's "t" test (Snedecor, 1956): 
N.S. =not significant (P ~ 0.05). 
SIGN. =significant difference, (P ~ 0.05). 
FIG. 7 . PRELIMINARY STUDY : ACTOPHOTOMETRIC METHOD FOR 
MEASURING GROSS ACTIVI TY IN MALE ALBINO RATS. 
TYPICAL DATA GENERATED BY TWO UNTREATED GROUPS 
OF RATS . INCREMENTAL COUNTS PER 30 MINUTES FOR 
6 HOURS. 
~ Counts/30 ~ 
1200 
1000 
800 
600 
400 
200 
0 
Means , group 1 , 
(0) 
Means , 
group 2 , 
(6) 
1 2 3 
C Values 3 
200 
C Values, group 2, 
( 6) 
4 5 6 
Solid symbols designate significant 
difference (P ~ 0.05), group 1 vs. group 2. 
69 
70 
TABLE 15 
PRELIMINARY STUDY: ACTOPHOTOMETRIC METHOD FOR MEASURING GROSS ACTIVITY IN 
MALE ALBINO RATS 
TYPICAL DATA GENERATED BY TWO UNTREATED GROUPS OF RATS RUN IN THE ACTOPHOTO-
METER FOR 6 HOURS. TOTAL CUMULATIVE COUNTS PER HOUR. 
DATA FROM CAGE I LENGTH OF STUDY: 12 DAYS 
TIME (hr) GROUP 1 (odd da~s) GROUP 2 (even da~s) COMPARISON 
x S.D. C(3) x S.D. C(3) group 1 vs group 2 
1 1794 630 35 1367 340 25 N.S. 
2 1926 764 40 1466 350 24 N.S. 
3 1956 764 39 1522 449 30 N .S. 
4 1991 743 37 1647 374 23 N.S. 
5 2329 599 26 1924 305 16 N.S. 
6 2907 745 26 2267 302 13 N.S. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, s .D./X x 1003. 
The mean ± S.D. of total cumulative counts generated at each of the 
6 hours by group 1, three rats run in the cage on the odd days (days 1, 
3,5,7,9,11) was computed. Each of the 6 means! S.D. was compared to 
the mean ! S.D. of counts generated at the same hour by group 2, three 
rats run in the cage on the~ days (days 2,4,6,8,10,12). Comparisons 
were made by means of Student's "t" test (Snedecor, 1956): 
N.S. =not significant (P $ 0.05). 
FIG. 8. PRELIMINARY STUDY : ACTOPHOTOMETRIC METHOD FOR 
MEASURING GROSS ACTIVITY IN MAI.E ALBINO RATS. 
TYPICAL DATA GENERATED BY TWO UNTREATED GROUPS OF 
RATS. TOTAL CUMULATIVE COUNTS PER HOUR FOR 6 HOURS. 
Total Cumulative Counts 
2800 
2400 
2000 
1600 
1200 
800 
400 
0 
C Values , 
group 1, ( 0) 
--l.Y-----10--_:~ 
C Values , 
group 2, ( 6) 
Tota 1 Counts, 
group 1, ( 0) 
Total Counts, 
group 2, ( 6) 
.£Values, 3 
60 
40 
20 
=-~~-'-~~___....._~~_._~~__.~~~~~~_....~__..o 
1 2 3 4 5 6 
~(hr) 
No significant difference 
(PS 0,05), group 1 vs . group 2 . 
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FIG. 9. PRELIMINARY STUDY : ACTOPHOTOMETRIC METHOD FOR MEASURING 
GROSS ACTIVITY I N MALE ALBINO RATS. MEANS ! STANDARD 
IEVIATIONS OF ALL C VALUES IN 22-DAY STIJ DY. 
~Values, 3 
250 
200 
150 
100 
50 
C Values ! S.D. of 
count s/30 minutes ( 0) 
C Values t S.D. of 
72 
total cumulative counts/hour 
( 6,) 
0 1 4 5 6 
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TABIE 16 
PRELIMINARY STUDY: ACTOPHOTOMETRIC METHOD FOR MEASURING GROSS ACTIVITY IN 
MAIE ALBINO RATS 
INCIIENCES OF SIGNIFICANT DIFFERENCES BETWEEN TWO UNTREATED GROUPS OF RATS, 
USING INCREMENTAL COUNTS PER 30 MINUTES FOR 6 HOURS . 
LENGTH OF STUDY: 22 DAYS 
TIME (hr) PORTION OF STUDY ANALY2ED 
DAYS 1-22 DAYS 1-12 DAYS 9-22 
11 runs/group 6 runs/group 7 runs/group 
I, Illa III I, 
1 I, I, II, III 
2 
3 
4 
II I, II 
5 I 
6 I I I 
a: Roman numerals indicate the actophotometer cage in which the significant 
change occurred. Four cages (I-IV) were used. In each cage the mean 
± S.D. of counts generated during each of the 12 half-hour periods by 
one group of 3 rats run on the odd days (days 1,3,5,7, ... ) was computed. 
Each of the 12 means ± S . D. was-COmpared to the mean ± S.D. of counts 
generated during the same half-hour interval by a similar group of 3 rats 
run in the same cage on the even days (days 2,4,6,8, ... ). Comparisons 
were made by means of Studen~"t" test ( Snedecor, 1956) and significant 
differences (P ~ 0.05) are noted above, by indicating the cage and the 
time-interval in which the change occurred. 
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TABLE 17 
PRELIMINARY STUDY: ACTOPHOTOMETRIC METHOD FOR MEASURING GROSS ACTIVITY IN 
MAIE ALBINO RATS 
INCIDENCES OF SIGNIFICANT DIFFERENCES BETWEEN TWO UNTREATED GROUPS OF RATS, 
USING TOTAL CUMULATIVE COUNTS PER HOUR FOR 6 HOURS. 
IBNGTH OF STUDY: 22 DAYS 
TIME (hr) PORTION OF STUDY ANALYZED 
DAYS 1-22 DAYS 1-12 DAYS 9-22 
11 runs/group 6 runs/group 7 runs/group 
1 Ia I 
2 I 
3 I 
4 I, II 
5 I, II II I' II 
6 I, II II I, II 
a: Roman numerals indicate the actophotometer cage in which the significant 
change occurred. Four cages (I-IV) were used. In each cage the mean 
± S.D. of total cumulative counts generated at each of the 6 hours by 
one group of 3 rats run on the odd days (day 1,3,5,7, . . . ) was computed. 
Each of the 6 means ± S.D. was compared to the mean± S.D. of counts 
generated at the same hour by a similar group of 3 rats run in the same 
cage on the~ days (days 2,4,6,8, ... ). Comparisons were made by means 
of Student's "t" test (Snedecor, 1956) and significant differences 
(PS 0.05) are noted above, by indicating the cage and the hour in which 
the change occurred. 
TABLE 18 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
A. SUMMARY OF DATA GENERATED BY TWO VEHICLE-TREATED GROUPS OF RATS RUN 
75 
IN THE ACTOPHOTOMETER FOR 6 HOURS. INCREMENTAL COUNTS PER 30 MINUTES. 
DATA FROM CAGE I LENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even da~s) GROUP 2 (odd da~s) COMPARISON 
(vehicle-treated) (vehicle-treated) 
x s.o. C(%) x S.D. C(3) group 1 vs. group 2 
! 881 123 14 1139 250 22 N.S. 8 
1 106 53 50 284 253 89 N.S. 
ll 10 6 60 127 208 164 N.S. 
2 3 ; 67 4 5 25 N.S. 
2! 6 4 67 4 4 100 N.S. 
3 22 38 173 66 141 214 N.S. 
3! 19 21 110 29 41 141 N.S. 
4 44 48 109 6 8 133 N.S. 
4! 9 9 100 6 6 100 N.S. 
5 9 8 89 43 69 160 N.S. 
5! 23 30 130 5 5 100 N.S. 
6 107 192 179 75 92 123 N.S. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, S.D./X x 1003. 
The mean ! S.D. of counts generated during each of the 12 half-hour periods 
by group 1, three rats injected daily with vehicle and run in the cage on 
the even days (days 0,2,4,6,8,10) was computed. Each of the 12 means 
! S.D. was compared to the mean ± S.D. of counts generated during the same 
half-hour interval by group 2, a similar group of 3 rats injected daily 
with vehicle and run on the odd days (days 1,3,5,7,9). Comparisons were 
made by means of Student's "t" test (Snedecor, 1956). 
a: N.S. indicates that for the given time-interval of 30 minutes there was no 
difference in the activity of the two groups of rats (P ~ 0.05). 
Dose: Vehicle (glass-distilled water), 1 ml/kg daily, i.p. 
TABLE 19 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
B. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICLE-TREATED RATS AND BY A 
GROUP OF THYROXINE-TREATED RATS RUN IN THE ACTOPHOTOMETER FOR 6 HOURS. 
INCREMENTAL COUNTS PER 30 MINUTES. 
DATA FROM CAGE II LENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even dals) GROUP 2 (odd dals) COMPARISON 
(Thyroxine-treated) (Vehicle-treated) 
76 
x S.D. C(3) x S.D. C(3) group 1 vs. group 2 
a 
! 707 211 30 1558 493 32 IEC. 
1 134 61 46 623 455 73 N.S. 
l! 42 37 SR 181 158 88 N.S. 
2 60 45 75 30 29 97 INC. 
2! 77 34 44 10 10 100 INC. 
3 64 52 81 85 161 189 N.S. 
3! 73 37 51 41 48 117 N.S. 
4 61 43 70 46 35 76 N.S. 
4.1 2 99 89 90 121 149 123 N.S. 
5 132 133 101 20 16 80 N.S. 
51. 2 84 71 85 45 59 131 N.S. 
6 105 89 85 282 262 93 N.S. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, S.D./X x 1003. 
The mean ± S.D. of counts generated during each of the 12 half-hour 
periods by group 1, three rats injected daily with thyroxine and run in 
the cage on the even days (days 0,2,4,6,8,10) was computed. Each of the 
12 means ± S.D. was-compared to the mean ± S.D. of counts generated 
during the same half-hour interval by group 2, a similar group of 3 rats 
injected daily with vehicle and run on the odd days (days 1,3,5,7,9). 
Comparisons were made by means of Student' s""""ttt" test ( Snedecor, 1956). 
a: For the given time-interval of 30 minutes the activity of the thyroxine-
treated rats relative to the vehicle-treated rats was DEC. (decreased), 
N.S. (not significantly different), or INC. (increased). (P ~ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Na Thlroxine, 1 mg/kg, 
days 0-4; 0.5 mg/kg, days 5-10. Daily, i.p. 
,, 
TABLE 20 
THE EFFECTS OF CHRONIC TilYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MAIE ALBINO RATS 
77 
C. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICLE-'IREATED RATS AND BY A 
GROUP OF PARGYLINE-TREATED RATS RUN IN TilE ACTOPHOTOMETER FOR 6 HOURS. 
INCREMENTAL COUNTS PER 30 MINUTES. 
DA TA FROM CAGE II I . LENGTil OF STUDY: 11 DAYS 
TIME (hr) 
X = mean. 
GROUP 1 (even days) 
(Pargyline-treated) 
x 
660 
290 
152 
208 
346 
218 
134 
81 
267 
321 
191 
639 
S.D. 
395 
225 
87 
133 
423 
276 
173 
111 
403 
491 
234 
730 
C(3) 
60 
78 
57 
64 
122 
127 
129 
137 
151 
153 
123 
114 
S.D. = standard deviation. 
GROUP 2 (odd days) 
(Vehicle-treated) 
x 
1705 
651 
297 
39 
58 
166 
73 
64 
177 
126 
28 
153 
S .D. 
600 
408 
347 
35 
46 
242 
57 
47 
235 
148 
21 
123 
C(3) 
35 
63 
117 
90 
79 
146 
78 
73 
133 
117 
75 
80 
C =coefficient of variation, S.D./X x 1003. 
COMPARISON 
group 1 vs. group 2 
a DEC. 
N.S. 
N.S. 
INC. 
N.S. 
N.S. 
N.S . 
N.S. 
N.S. 
N.S . 
N.S. 
N.S. 
The mean ! S. D. of counts generated during each of the 12 half-hour 
per i ods by gr oup 1, three rats injected daily with pargyline and run in 
the cage on the even days (days 0,2,4,6,8,10) was computed. Each of the 
12 means ! S.D. was-compared to the mean z S.D. of counts generated 
during the same half-hour interval by group 1, a similar group of 3 rats 
injected daily with vehicle and run on the odd days (days 1,3,5,7,9). 
Comparisons were made by means of Student's~" test (Snedecor, 1956). 
a: For the given time-interval of 30 minutes the activity of the thyroxine-
treated rats relative to the vehicle-treated rats was DEC . (decreased, 
N.S. (not significantly different) or INC . (increased). (PS: 0,05). 
Doses : Vehicle (glass-distilled water), 1 ml/kg . Pargyline HCl, 25 mg/kg. 
Daily, i.p. 
TABLE 21 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
D. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICLE-TREATED RATS AND BY A 
GROUP OF RATS TREATED WITH PARGYLINE AND THYROXINE, RUN IN THE ACTO-
PHOTOMETER FOR 6 HOURS. INCREMENTAL COUNTS PER 30 MINUTES. 
DA TA FROM CAGE IV LENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even dals) GROUP 2 (odd dals) COMPARISON 
(Pargyline + Thyroxine- (Vehicle-treated) 
treated) 
78 
x S.D. C(3) x S.D. C(3) group 1 vs. group 2 
a 
l. 626 251 40 1105 329 30 DEC. 2 
1 212 46 22 342 374 109 N.S. 
it 216 169 78 83 132 159 N.S. 
2 219 150 68 29 38 131 INC. 
2t 171 135 79 27 33 122 INC. 
3 186 174 94 17 8 47 N.S. 
3! 213 238 111 35 46 131 N.S. 
4 140 125 89 33 28 85 N.S. 
4! 233 295 127 96 171 178 N.S. 
5 192 250 130 40 39 98 N.S. 
st 105 63 60 77 99 129 N.S. 
6 218 136 62 158 242 153 N.S. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of "ariation, S.D./ X x 1003. 
The mean ! S.D. of counts generated during each of the 12 half-hour 
periods by group 1, three rats injected daily with pargyline and 
thyroxine and run in the cage on the even days (days 0,2,4,6,8,10) was 
computed. Each of the 12 means ± S.D. was compared to the mean ± S.D. 
of counts generated during the same half-hour interval by group 2, a 
similar group of 3 rats injected daily with vehicle and run on the odd 
days (days 1,3,5,7,9). Comparisons were made by means of Student's----
"t" test (Snedecor, 1956). 
a: For the given time-jnterval of 30 minutes the activity of the rats given 
pargyline and thyroxine, relative to the activity of the vehicle-treated 
rats, was IEC. (decreased), N.S. (not significantly different) or INC. 
(increased). (P ~ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Combined-treatment: 
Pargyline !!£!, 25 mg/1<:g; ~Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5-10. Daily, i.p. 
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TABLE 22 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MAIE ALBINO RATS 
E. SUMMARY OF DATA GENERATED BY TWO VEHICIE-TREATED GROUPS OF RATS RUN IN 
THE ACTOPHOTOMETER FOR 6 HOURS. TOTAL CUMULATIVE COUNTS PER HOUR. 
DA TA FROM CAGE I LENGTH OF STUDY: - 11 DAYS 
TIME (hr) GROUP 1 (even da~s) GROUP 2 (odd da~s) COMPARISON 
(Vehicle-treated) (Vehicle-treated) 
x S.D. C(3) x S.D. C(3) group 1 vs. group 2 
1 1423 484 34 987 133 14 N.S.a 
2 1554 558 36 1000 135 14 N.S. 
3 1625 570 35 1028 167 16 N.S. 
4 1659 595 36 1091 204 19 N.S. 
5 1709 618 36 1109 208 19 N.S. 
6 1769 570 32 1239 264 21 N.S. 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, S.D./X x 1003. 
The mean ! S.D. of total cumulative counts generated at each of the 
6 hours by group 1, three rats injected daily with vehicle and run in 
the cage on the even days (days 0,2,4,6,8,10) was computed. Each of 
the 6 means .± S ."i.5':""Was compared to the mean :.t S . D. of counts i:i;el"'orAtP.ci 
at the same hour by group 2, a similar group of three rats injected 
daily with vehicle and run on the odd days (days 1,3,5,7,9). Compari-
sons were made by means of Student'S"t" test (Snedecor, 1956). 
a: N.S. indicates that for the given interval of total lapsed time there 
was no difference in the activity of the two groups of rats. ( S 0.05). 
Dose: Vehicle (glass-distilled water), 1 ml/kg. Daily, i.p. 
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TABLE 23 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
F. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICIE-TREATED RATS AND BY A 
GROUP OF THYROXINE-TREATED RATS RUN IN THE ACTOPHOTOMETER FOR 6 HOURS. 
TOTAL CUMUIATIVE COUNTS PER HOUR. 
DATA FROM CAGE II LENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even da~s) GROUP 2 (odd da~s) COMPARISON 
(Thyroxine-treated) (Vehicle-treated) 
x S.D. C(3) x S.D. C(3) group 1 vs. group 2 
1 842 J."'7 ~l 2181 93" 43 TJEC. a 
2 944 260 28 2391 967 40 DEC. 
3 1084 242 22 2387 1095 44 DEC. 
4 1217 274 22 2574 1146 42 DEC. 
5 1448 275 19 2715 1094 40 N.S. 
6 1637 345 21 3042 1064 35 N.S. 
x = mean. 
S.D. = standard deviation 
c = coefficient of variation, S.D./X x 1003. 
The mean ± S.D. of total cumulative counts generated at each of the 
6 hours by group 1, three rats injected daily with thyroxine and run in 
the cage on the even days (days 0,2,4,6,8,10) was computed. Each of the 
6 means ± S.D. wascompared to the mean ± S.D. of counts generated at 
the same hour by group 2, a similar group of three rats injected daily 
with vehicle and run on the odd days (days 1,3,5,7,9). Comparisons 
were made by means of Studen~ "t" test (Snedecor, 1956). 
a: For the given total lapsed time-interval the activity of the thyroxine-
treated rats relative to the vehicle-treated rats was DEC. (decreased) 
or N.S. (not significantly different). (P ;$ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Na Thyroxine, 1 mg/kg, 
days 0-4; 0.5 mg/kg, days 5-10. Daily, i . p. 
TABLE 24 
'lliE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MAI.E ALBINO RATS 
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G. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICI.E-TREATED RATS AND BY A 
GROUP OF PARGYLINE-TREATED RATS RUN IN THE ACTOPHOTOMETER FOR 6 HOURS. 
TOTAL CUMULATIVE COUNTS PER HOUR. 
DATA FROM CAGE III I.ENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even dazs) GROUP 2 (odd dazs) COMPARISON 
(Pargyline-treated) (Vehicle treated) 
x S.D. C(3) x S.D. C(3) group 1 vs. group 2 
1 951 605 64 2355 964 41 IEC. a 
2 1310 640 49 2692 1291 48 N.S. 
3 1874 650 35 2916 1397 39 N.S. 
4 2090 717 34 3053 1397 46 N.S. 
5 2677 1212 45 3356 1682 50 N.S. 
6 3507 1134 32 3536 1736 49 N.S. 
x = mean •. 
S.D. = standard deviation. 
c = coefficient of variation, S.D.;X x 1003. 
The mean ! S.D. of total cumulative counts generated at each of the 
6 hours by group 1, three rats injected daily with pargyline and run in 
the cage on the even days (days 0,2,4,6,8,10), was computed. Each of 
the 6 means ± S.D. was compared to the mean t S.D. of counts generated 
at the same hour by group 2, a similar group of three rats injected 
daily with vehicle and run on the odd days (days 1,3,5,7,9). Compari-
sons were made by means of Student7S"t" test (Snedecor, 1956). 
a: For the given total lapsed time-interval the activity of the pargyline-
treated rats relative to the vehicle-treated rats was DEC. (decreased) 
or N.S. (not significantly different). (P ~ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Pargzline !!£!, 25 mg/kg, 
Daily, i.p. 
82 
TABLE 25 
TIIE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
H. SUMMARY OF DATA GENERATED BY A GROUP OF VEHICLE-TREATED RATS AND BY A 
GROUP OF RATS TREATED WITH PARGYLINE AND THYROXINE, RUN IN THE ACTO-
PHOTOMETER FOR 6 HOURS. TOTAL CUMULATIVE COUNTS PER HOUR. 
DA TA FROM CAGE IV LENGTH OF STUDY: 11 DAYS 
TIME (hr) GROUP 1 (even days) 
(Pargyline + Thyroxine-
treated) 
x S.D. C(3) 
1 838 270 32 
2 1274 380 30 
3 1631 636 39 
4 1984 962 49 
5 2409 1478 61 
6 2732 1617 59 
x = mean. 
S.D. = standard deviation. 
c = coefficient of variation, 
GROUP 2 (odd days) 
(Vehicle-treated) 
x S.D. C(3) 
1448 667 46 
1560 768 49 
1604 761 48 
1672 727 42 
1808 715 40 
2044 686 34 
s .D./X x 1003. 
COMPARISON 
group 1 vs. group 2 
N.S.a 
N.S. 
N.S. 
N.S. 
N.S. 
N .S. 
The mean ± S.D. of total cumulative counts generaterl at each of the 
6 hours by group 1, three rats injected daily with pargyline and 
thyroxine and run in the cage on the even days (days 0,2,4,6,8,10), was 
computed. Each of the 6 means ± S.D.-wa8 compared to the mean ± S.D. 
of counts generated at the same hour by group 2, a similar group of 
three rats injected daily with vehicle and run on the odd days (days 1, 
3,5,7,9). Comparisons were made by means of Student•s°"tt't" test 
(Snedecor, 1956). 
a: For the given total lapsed time-interval the activity of the rats 
given pargyline and thyroxine was N.S. (not significantly different) 
from the activity of the vehicle-treated rats. (P~ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Combined-treatment: 
Pargyline .!!£!, 25 mg/kg; ~ Thyroxine, 1 mg/kg, days 0-4; 0.5 mg/kg, 
days 5-10 . Daily, i.p . 
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TABLE 26 
SUMMARY 
TIIE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREA'IMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
INCIDENCES OF SIGNIFICANT DIFFERENCES BETWEEN DRUG-TREATED AND VEHICLE-
TREATED GROUPS OF RATS, USING INCREMENTAL COUNTS PER 30 MINUTES FOR 6 HOURS. 
LENGTH OF STUDY: 11 DAYS 
IV. Vehicle vs. 
TIME (hr) 
I~ Vehicle vs. 
Vehicle 
II. Vehicle vs. 
Thx:roxine 
DEC.b 
INC. 
III. Vehicle vs. Thyroxine + 
Parglline Parglline 
DEC. DEC. 
iNcb INC. 
INC. 
a: Roman numerals indicate the actophotometer cage. Four cages (I-IV) were 
used. In each cage the mean ± S.D. ~f counts generated during each of the 
12 half-hour periods by a group of three rats treated daily with vehicle 
and run on the odd days (days 1,3,5,7,9) was computed. Each of the 12 
means ± S.D. wa'S"Compared to the mean ± S.D. of counts generated during 
the same half-hour interval by a similar group of three rats, treated daily 
with vehicle (I), thyroxine (II), pargyline (III) and thyroxine + pargyline 
(IV), and run on the even days (days 0,2,4,6,8,10). Comparisons were made 
by means of Student's~ test (Snedecor, 1956). 
b: DEC. or INC. indicate that for the given time-interval of 30 minutes the 
drug-treated rats were less active or more active, respectively, than the 
vehicle-treated rats in the same cage at the same time-interval. (P ~ 0.05). 
Dose: Vehicle (glass-distilled water), 1 ml/kg. ~Thyroxine, 1 mg/kg, 
days 0-4; 0.5 mg/kg, days 5-10. Pargyline HCl, 25 mg/kg. Daily, i.p. 
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TABIB 27 
SUMMARY 
THE EFFECTS OF CHRONIC THYROXINE AND PARGYLINE TREATMENT ON LOCOMOTOR 
ACTIVITY IN MALE ALBINO RATS 
INCIDENCES OF SIGNIFICANT DIFFERENCES BETWEEN DRUG-TREATED AND VEHICIB-
TREA TED GROUPS OF RA TS, US ING TOTAL CUMULATIVE COUNTS PER HOUR FOR 6 HOURS. 
IBNGTH OF STUDY : 11 DAYS 
IV. Vehicle vs. 
I.a Vehicle vs. II. Vehicle vs . III . Vehicle vs. Thyroxine + 
TIME (hr) Vehicle Thyroxine Pargyline Pargyline 
1 DEC. b me. 
2 DEC . 
3 DEC . 
4 DEC. 
5 
6 
a: Roman numerals indicate the actophotometer cage. Four cages (I-IV) were 
used. In each cage the mean ! S.D . of total cumulative counts generated 
at each of the 6 hours by a group of three rats treated daily with vehicle 
and run on the odd days (days 1 0 3,5 , 7 , 9) was computed. Each of the 6 
means ! S.D . wa'SCompared to the mean ± S.D. of counts generated at the 
same hour by a similar group of three rats, treated daily with vehiclP. (I), 
thyroxine (II) , pargyline (III) , and thyroxine + pargyline (IV), and 
run on the even days (days 0,2 , 4,6 , 8 , 10) . Comparisons were made by means 
of Student'~" test (Snedecor , 1956). 
b : DEC . indicates that for the given total lapsed time the drug-treated rats 
were less active than the vehicle-treated rats in the same cage at the 
same total lapsed time . (P ~ 0.05). 
Doses: Vehicle (glass-distilled water), 1 ml/kg. Na Thyroxine, 1 mg/kg, 
days 0-4 ; 0.5 mg/kg, days 5- 10 . Pargyline HCl, 25 mg/kg. Daily, i.p. 
V. DISCUSSION 
A. Blood Pressure Studies 
The systolic blood pressures of the thyroxine- treated rats was signi-
ficantly increased over the control group on day 2 of drug treatment (Table 1 
and Figure 1). Determinations were again made on days 7, 10, 12, 16 and 19, 
and during this period the mean systolic pressure ! S . D. of the thyroxine-
treated rats increased steadily from 131 ± 3 mm Hg on day 7 to 184 ± 2 mm Hg 
on day 19. During the same period mean systolic pressures in the control 
group ranged from 113 ! 7 to 121 ± 7 mm Hg. Rats receiving pa r gyline exhibited 
no significant changes from the control group on day 2. On day 7, however, 
systolic pressure was significantly decreased in the pargyline-treated rats, 
and remained lowered for the rest of the study. The range was 83 ± 10 to 
94 ± 13 mm Hg during days 7 to 19 ; from Figure 1 it can be seen that once the 
hypotension was established it remained constant within a range of 11 mm Hg. 
The range of the controls in this period was 8 mm Hg . 
Rats receiving both thyroxine and pargyline showed no significant 
change in systolic blood pressure on day 2 of drug treatment . In a second 
study (Table 2), it was shown that no significant change in a similarly-
treated group of rats had occurred by day 3 of treatment . Mortality in rats 
receiving both thyroxine and pargyline prevented, in both studies, the deter-
mination of blood pressures beyond days 2 or 3 , respectively. This degree of 
mortality was not observed, however , in other rats receiving both drugs but 
not subjected to the blood pressure determination procedur e . It is postulated, 
then, that in some way the blood pressure procedure was stressful enough to 
cause relatively early death in these animals but not in animals receiving 
thyroxine alone or pargyline alone. It is possible that the incubation at 
40°C for 20 minutes precipitated the mor tality . Hyperthyroid animals are 
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characteristically intolerant to heat (Morgans, 1964) but if this factor 
alone were causing the deaths then mortality in the thyroxine-treated rats 
would have also been high. This, however, did not occur . 
Qualitative observations noted by the investigator in the course of 
this study appear to be of interest. No quantitative measurements were made 
of heart rate or of diastolic pressure. Nevertheless, in the thyroxine-
treated group the hypertension was accompanied by a very obviously increased 
heart rate and greatly increased excursions between the systolic peak and 
the diastolic trough , as seen on the oscilloscope screen. An increase in 
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the difference between systolic and diastolic pressures generally indicates 
increased stroke volume in the heart. If at the same time the heart rate is 
increased a net increase in cardiac output might be postulated. These two 
phenomena were repeatedly observed on each day that determinations were made. 
Furthermore, the same effects were seen in rats receiving both thyroxine and 
pargyline, but in these animals there was no elevation of systolic pressure. 
Finally, rats receiving pargyline alone appeared to exhibit slightly reduced 
heart rate and definite decreases in the excursions between systolic peaks 
and diastolic troughs. This group of rats exhibited hypotension during the 
times when these effects were noted. 
In view of these observations it is interesting to note that Brest 
et al. (1964) found no change in the cardiac output of hypertensive patients 
treated with pargyline, and Sutnick !:..! ~· (1964) found no change in the 
pulse rates of hypertensive patients in whom pargyline administration pro-
duced a marked hypotensive response. Smith (1965) showed, however, that 
pretreatment with pargyline (100 mg/kg) 12 hours before sacrifice reduced 
the heart rate of isolated guinea pig atria. 
It is the opinion of the investigator that thyroxine produced an in-
crease in heart rate and cardiac output as well as the measured increase in 
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systolic pressure. This view is in accord with the hemodynamic effects seen 
in hyperthyroid conditions. These effects have been discussed above 
(Wurtman ~ !.!.· • 1964 ; Danowski ~ al., 1964 ; Barker~.!!_. , 1965; Bray, 
1964). 
Pargyline definitely prevented the hypertension induced by thyroxine. 
In rats receiving both drugs no increases over control values of blood pres-
sure were seen. The observation that pargyline appears not to block the 
tachycardia and increased systolic- diastolic excursions in rats receiving 
both drugs favors the view that the hypotensive effect of MAO inhibitors 
is mediated by a decreased peripheral resistance (Kopin~ !1:,., 1964; 
Goldberg, 1964). But inasmuch as the _ats eceiving pargyline alone did 
appear to exhibit reduced heart rate and systolic- diastolic excursions, it 
cannot be stated categorically that pargyline had no effect at all on the 
heart. 
It is hoped that no confusion will result from the inclusion of quali-
tative observations made in this work. Speculation based on these observations 
is intended only to provide a further asis ~ or interpreting the measured 
hemodynamic effects obtained in this study. 
B. Urinary Sodium and Potassium Studies 
It can be seen from Tables 3 and 4 and Figures 2 and 3 that thyroxine 
treatment in rats was accompanied by significantly increased (P < 0 . 05) 
urinary output of potassium and sodium beginning on day 6 of treatment. The 
failure of sodium output to be signif i cantly increased on day 8 of the study 
is probably unimportant in view of significant increases on days 6, 7 and 10. 
These results are in accord with the report of Williams and Bakke (1962) 
that both sodium and potassium excretion are increased in hyperthyroidism. 
Treatment with pargyline reduced the mean values of urinary potassium 
and sodium when compared to the controls, but except for a decreased potassium 
output on day 8 these lowered values were not statistically significant. It 
is very interesting, however, that rats receiving both thyroxine and pargy-
line did not exhibit a statistically significant increase in urinary sodium 
and potassium excretion. There was only one exception: sodium excretion on 
day 6 was significantly increased. Thus in these animals sodium and potas-
sium excretion was increased, but not significantly so, over the controls. 
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Pargyline has been reported to moderately reduce the glomerular fil-
tration rate in humans (Brest~!!.!. ·• 1964; Onesti ~ !!.!.·• 1964). If this is 
also happening in rats receiving pargyline, less sodium and potassium would 
be expected to enter the kidney tubules and, presumably, less might be excreted . 
The data obtained from rats receiving both drugs might prompt one to speculate 
that by effecting a reduction in glomerular filtration rate, pargyline reversed 
the outflow of sodium and potassium caused by thyroxine. The slight, although 
insignificant, reduction in excretion of sodium and potassium in animals re-
ceiving pargyline alone lends support to this view. It must be emphasized, 
however, that these data in no way suggest that pargyline is causing a reten-
tion of sodium and potassium. Animals receiving pargyline exhibited sodium 
and potassium excretion patterns that although falling on one side or another 
of the control values were not different, statistically, from control values. 
C. Weight ~ Studies 
Many investigators have shown that animals treated with various forms 
of the thyroid hormones lose weight or do not gain weight at the same rate as 
untreated animals (Kekki, 1964; Evans~!.!,., 1964; D'Angelo and Grodin, 1964; 
Moury~!!.!.·• 1964; Logothetopoulos, 1963). In these and other studies the 
body weight status of the animals has been determined in various ways. Com-
paring gross weights of the treated animals to the gross weights of the un-
treated controls is valid only when starting weights of both groups do not 
differ (Jackson, 1962). Weight is sometimes expressed as per cent of animal 
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weight on the first day of drug treatment, or by subtracting beginning weight 
from final weight at the end of the study. 
Because weight loss is the simplest indication of hyperthyroidism it 
was decided early in this work to use the weight parameter as a determinant 
of hyperthyroidism in the rats treated with thyroxine. The daily weights of 
1 
the 24 animals in the blood pressure study were accordingly used as a start-
ing point for weight analysis. 
There was no significant difference, on day 0 of the study, between the 
weights of the control group and each of the 3 experimental groups. Accord-
ingly, the total weights of the control group were compared to the total 
weights of each experimental group on each day of the study. (Table 5 and 
Figure 4). It was found that a significant difference between the control 
group and the thyroxine-treated group occurred on day 7 of the study, and 
persisted until the end of the experiment. The animals receiving pargyline 
showed no change in total weight from the total weight of the controls through-
out the study. Finally the total weights of the animals receiving both 
thyroxine and pargyline were not differe nt from the controls on any day of 
the study. 
The thyroxine-treated animals had exhibited significant hypertension 
on day 2 of the study. It seemed likely, then, that these animals were in 
fact hyperthyroid; yet the decrease in weight was not seen until day 7. Thus, 
it seemed to the investigator that the use of tbtal weights for an indication 
of weight status in the animals might not be a particularly sensitive method. 
Accordingly the cumulative weight gain from day 0 was calculated for 
each animals used in the study . This was done simply by subtracting the weight 
1. See Summary of Experimental Design, Page 28. 
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of the animal on day O from its weight on each successive day . In this way 
a record of weight gain from beginni ng of treatment was obtained for each 
animal. The means ! standard deviations of these values were determined 
and the cumulative weight gains of the control group were compared to the 
gains of each of the 3 experimental groups, for each day of the study. 
These data are summarized in Table 6 and Figure 5 . It is obvious 
that beginning on day 2 and persisting for the remainder of the experiment, 
weight gains in the thyroxine - treated group were significantly lower than 
control values. Moreover, these animals exhibited negative weight gains: 
that is, they lost weight. After 19 days of treatment these rats were 
49 ! 8 g lighter than their individual starting weights; the control rats on 
day 19 were 61 ± 17 g heavier than their individual starting weights . 
The fact that weight loss and hypertension in thyroxine-treated rats 
both became significant on day 2 is probably not of outstanding importance. 
But one might expect these 2 phenomena to occur within a fairly short period 
of time. 
Rats receiving both thyroxine and pargyline exhibited significant 
weight loss from day 1 to the end of the study, except for day 3, for which 
the comparison to the controls showed no significant change . This one value 
is negligible, however , in view of the overall weight pattern . This weight 
loss in the animals receiving both drugs was completely obscured when total 
weights were used for comparison. 
From day 3 to day 14 inclusive the pargyline-treated animals exhibited 
a significant decrease in weight gain. This disappeared on day 15. It is 
difficult to understand this curious phenomenon. Perhaps the stress of 
being subjected to the blood-pressure procedure resulted in a transient 
weight loss which disappeared as the rats adapted to the stress . Since all 
animals consumed all food offered to them, decreased food intake is ruled 
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out as a causative factor. In other pargyline-treated animals (to be dis-
cussed below) not subjected to blood pressure determinations , no weight loss 
occurred. It is tempting to specu late ~hat stress i s the factor. Guarino 
!:.! ~ · (1964) showed that isolated rats treated with the same daily dose of 
pargyline as was used in this work showed irritability and 283 more brain 
serotonin than similarly- treated rats housed in pairs . Isolation was deemed 
to be stressful . Isolation was not a factor in the present work, however, 
and the rats showed no irritability. 
A third method of weight analysis was carried out. Daily weight gains 
were computed for each animal by subtracting total weight on day 1 from total 
weight on day 2, then day 2 weight from day 3 weight, successively to day n-1 
from day n. These data are summarized in Table 7. No trends could be estab-
lished , and it is probable that because of the large standard deviations no 
useful information can be derived from this kind of weight analysis. 
It was concluded , then , that only the cumulative weight gains from 
day 0 of treatment afforded a sensitive method for detecting drug-induced 
changes in weight. This method was accordingly used in the principal study 
1 
of phase 2 of this work to determine weight patterns in the animals used for 
electrolyte and activity studies. Results are summarized in Table 8 and 
Figure 6. Thyroxine-treated rats lost weight significantly; pargyline-treated 
rats showed no · significant change from the controls, and rats receiving both 
pargyline and thyroxine lost more weight than the thyroxine- treated rats. 
It should be emphasized that with very infrequent exceptions all rats 
in these studies consumed all the food offered to them . These weight patterns 
are, then,a reflection of food util i zation rather than food consumption, inas-
much as each group of 3 rats was offered 60 g of food per day and was observed 
to consume all of it. 
1. See Summary of Experimental Design , Page 28 . 
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The weight loss in hyperthyroid ra t s is a well-known phenomenon that 
need not be elaborated . Its appearan~e in this work confirms the efficacy 
of the dose of thyroxine in produc ing hyperthyroi dism . 
D. Monoamine Oxidase Studies 
The decision to use mitochondria suspended in hypotonic phosphate 
buffer in the assay for MAO was based on several considerations. Earlier 
papers (Hawkins , 1952 ; Zile and Lardy , 1959) indicated that most of the MAO 
activity was to be found in the mitochondria . More recently, Oswald and 
Strittmatter (1963) indicated that 76.73 of the MAO activity of a rat liver 
homogenate was recovered in the mitochondria . They suggested that the minor 
MAO activit ies distributed among nuclear , lysosomal and supernatant frac-
tions represented mitochondrial contamination ; but the 12 . 63 activity found 
in the microsomes was in excess of mitochondrial contamination. Baudhuin 
.!;,! ~ · (1964) found that 743 of total MAO activity in rat liver homogenate 
was recovered in the mitochondria ; 243 was found in the microsomes. Thus it 
appeared reasonable to use mitochondria for the assay of MAO. 
In Table 9 the results of a purification study are reported. It can 
be seen that mitochondria from homogenates of liver and brain had 1503 and 
2003 respectively greater MAO activity than the homogenates from which they 
were isolated . Guha and Murti (1965) reported a 2103 increase of MAO activity 
in mitochondria isolated from rat liver homogenates. 
Because of the large numbers of animals used in this study it was im-
possible to run MAO assays on freshly isolated mitochondria from brains and 
livers . Some method of preservation was therefore indicated . Seiden and 
Westley (1962) reported that lysed brain mitochondria stored in 0 . 05 M phos-
phate buffer (pH 7.4) at - 4o0 c for two months did not lose MAO activity 
appreciably. Their assay was run , however , on soluble MAO isolated by soni-
fication of the thawed lysed mitochondria . This method of obtaining soluble 
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MAO is appropriate only for in vitro studies. Thus it is not suitable for 
studying the effects on MA0 9 as assayed in ~. of drugs administered 
in ~· It was dec i ded 9 then , to assay lysed mitochondria that were re-
homogenized and suspended in 0 . 05 M phosphate buffer (pH 7.4). A stability 
study on this preparation is reported in Table 10 . Aliquots of freshly 
prepared brain and liver mitochondria were assayed and the remaining ali-
0 quots were put into separate tube and frozen at - 40 C for subsequent 
thawing and assay at various time intervals. It can be seen from Table 10 
that the MAO activity of lysed brain mitochondria remained unchanged after 
101 days of freezing. Frozen liver mitochondria were assayed as far as 
85 days after freezing p and also appeared to be stable. Thus it was deemed 
feasible to individually prepare for freezing and subsequent assay the mito-
chondria from many animals . This factor permitted the design of a relatively 
large-scale experiment on the last day of which as many as 40 or 50 animals 
might be sacrificed for preparation of brain and liver mitochondria. The 
mitochondria could then be assayed for MAO activity at convenient times 
within several months following sacrifice . 
In the preparation of liver mitochondria lower relative centrifugation 
force ("r.c . f." or "g" value) was employed than that used by Myers and Slater 
(1957). The three successive centrifugations at 300 x g, 2000 x g and 
4600 x g instead of the 800 x g p 6000~7000 x g and 18000 x g used by Myers 
and Slater probably resulted in a lower mitochondrial yield , consisting pri-
marily of "heavy" mitochondria (Baudhuin =!. ~., 1964) with some contamination 
by other cell components. Since the other cell components contain small or 
negligible amounts of MAO activity p as already seen , contamination by these 
would result only in a somewhat lower degree of enzyme activity per mg pro-
tein . The fact that MAO activity in the liver mitochondria prepared in this 
work was 1503 of homogenate activity instead of the 2103 reported by Guha and 
Merti (1965) is probably a reflection of the presence of inactive cell 
components with the mitochondria. 
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In the present work MAO assays of bra i n and liver mitochondria were 
run within 45 days after termination of the experiment . Results are re-
ported in Tables 11 and 12 and summarized i n Table 13. 
In Tables 11 and 12 it can be seen that daily administration of 
vehicle did not alter terminal MAO activity in brain or liver after 12, 18 
or 28 days of treatment . Accordingly , mitochondrial MAO activity for all 9 
animals treated with vehicle for the various periods of time was summarized 
in Table 13 as 0,83 ~ 0.24 pmol kynuramine/hr/mg protein in brain and 2.86 
± 0.79 such units in liver. The livers of animals treated with thyroxine 
had a MAO activity of 2.17 ± 0.77 pmol kynuramine/hr/mg protein , and in the 
brains of these animals MAO activity was 0.72 ± 0 . 11 such units. Both in 
brain and liver there was no statistical d i fference (P ~ 0.05) between the 
MAO activity of the thyroxine-treated animals and the control animals. 
That thyroxine treatment did not alter MAO activity in brain is in 
agreement with the work of Zile (1960). Moreover , Tata (1964) has reported 
that the brain concentrates radioactive thyroxine and radioactive tri-
iodothyronine hardly at all. Thus it appears possible that thyroxine treat-
ment might not alter brain MAO activity because of lack of sustained contact 
of the hormones with brain tissue . 
Daily treatment with thyroxine did not significantly alter MAO activity 
in rat liver mitochondria . Wurtman ~ ~· (1963) reported similar results 
using the same dose of Na thyroxine (1 mg/kg) as in the present work. These 
investigators did find , however , a small but significant decrease in liver 
MAO activity when the daily dose of Na thyroxine was increased to 2 . 5 mg/kg, 
or higher. Moreover , they showed that hepatic COMT activity was unaffected 
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after daily treatment with the lower dose of thyroxine but was similarly 
lowered after treatment with the higher dose. D' Iorio and Leduc (1960) had 
also reported decreased liver COMT activity after da i ly injection of rats 
with 2.5 mg/kg of Na thyroxine. Wurtman ,!! ~· suggested that these decreases 
in rat liver MAO and COMT activity seen only after daily treatment with very 
high doses of thyroxine might represent a toxic effect. 
In view of the results of Wurtman et al. and of the present study 
wherein no decrease of rat liver MAO activity was seen after thyroxine treat-
ment , it is difficult to understand the decreased liver MAO activity reported 
by several investigators and already reviewed above in the literature survey 
section. It appears that these investigators did not use toxic doses of thy-
roid hormones; consequently the method of MAO assay must be considered. It 
was seen above that in every study of decreased liver MAO activity following 
thyroid administration, manometric techniques were employed using tyramine as 
substrate. Moreover , in each study it appeared that enzyme preparations con-
taining lysed, swollen or aged mitochondria were used . Aebi (1962) showed 
that when manometric techniques were used for the assay of MAO with tyramine 
as substrate greater o2 utilization or NH3 production was seen in disrupted 
mitochondria than in intact mitochondria. He also pointed out that it is very 
difficult to extrapolate results of MAO studies on lysed mitochondria to events 
in the intact cell . Thus it appears that the use of manometric techniques for 
assays of MAO may require that greater attention be paid to the physical state 
of the mitochondria used in the study . 
The range of values obtained in manometric assays of rat brain MAO acti-
vity is apparently quite wide . Zile and Lardy (1959) reported that MAO activity 
+ in the liver mitochondria of 22 normal rats was 7 . 5 patoms o2/mgN/hr, - 1.1 
standard error (S.E . ). Similar mitochondria from 19 thyroid-fed rats had MAO 
activity of 3 . 6 such units! 1.2 S.E. One can calculate the standard deviations 
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in this work, using the formula: S.D = S .E . x the square root of the sample 
size (Snedecor , 1956) . The recalculated MAO activ i ty values (means! S.D) 
in the work of Zile and Lardy are 7 . 5 z 5 . 2 for controls and 3 . 6 ± 5 . 3 for 
thyroid- fed animals . The number of assays was apparently large enough, how-
ever , to show a statistically significant decrease (P = 0.015) in the liver 
activity of these thyroid-fed rats. Nevertheless the obviously wide range 
of individual values may reflect in part the variable state of the mito-
chondria in the preparation used by these investigators. 
Wurtman !:,! .!.!_. (1963) suggested that because thyroxine induces mito-
chondrial swelling and inhibits mitochondrial oxidative systems it could 
interfere with MAO activity by affecting mitochondrial structure and energy 
production. In the present study the investigator used lysed mitochondria 
because it was desirable to bypass the structural changes induced by thyroxine. 
In this way any influence that injected thyroxine might have on MAO might be 
interpreted as a direct action on the enzyme itself . It appears possible from 
this work that thyroxine does not directly inhibit the enzyme in vivo. 
From Tables 11, 12 and 13 it is quite obvious that daily treatment with 
pargyline for as little as 11 days reduced the MAO activity in rat brain and 
liver mitochondria to O. 1003 inhibition of an enzyme after treatment in vivo 
with a potent inhibitor is not uncommon . Weber!:,!.!.!_. (1965) reported that 
after a single dose of pargyline (50 mg/kg) or iproniazid (150 mg/kg) given 
subcutaneously brain MAO activity in rats was suppressed 1003. McNeil! (1964) 
found that 3 hours after intraperitoneal administration of phenelzine (30 mg/kg) 
to rats brain MAO activity was suppressed 97.53 and liver MAO activity was 
significantly suppressed 32.63. It was not unusual , then, to find that daily 
treatment with pargyline for 11 days or longer totally suppressed MAO activity 
in liver and brain . 
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Total suppression of MAO activity was also seen in brains and livers 
of rats receiving both pargyline and thyroxine (Tables llp 12 and 13). Since 
treatment with pargyline alone completely suppressed MAO activity in brain 
and liver these results are not at all surprising. 
E. Activity Studies: The Method. 
The actophotometer was chosen for the evaluation of locomotor responses 
in rats treated with pargyline, thyroxine or both pargyline and thyroxine be-
cause use of this cage is completely objective in respect to generation of 
data. 
Rats have not been extensively used in photoelectric recorder-activity 
cages. It was necessary, therefore, to first establish a method in which 
limitations and sensitivity were known. Watzman et al. (1964) carried out 
an extensive study evaluating different parameters involved in the programming 
of the actophotometer for activity studies. These investigators used groups 
of 5 mice per cage and took readings every 15 minutes for 2 hours. From their 
study the following facts emerged. These were used or adapted for use in the 
present study. 
1. The use of 5 mice resulted in highest counts and lowest 
coefficient of variation (S.D./mean, x 100%, the "C" value). 
2. The C value was lowest in the first half hour. 
3. There was significant variation from cage to cage. 
4. Use of different types of housing and lighting in the 
room appeared not to modify animal response to drugs 
as measured in the actophotometer. 
5. Fasting mice generated higher counts than satiated mice. 
6. No "warmup" period or equilibrating period was employed; 
counters were turned on immediately after mice were placed 
in the actophotometer cages. 
In the present work a preliminary study utilizing untreated rats was 
first carried out. The method has been presented above but is summarized here 
for convenience. 
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Three rats were put into an actophotometer cage; the counters were 
turned on immediately and total counts appearing every 30 minutes for 6 hours 
were recorded. The group of 3 rats was placed in the cage every other day. 
On the alternate days another, similar group of 3 rats was placed in the cage 
and counts were recorded in similar fashion. In this way, after 12 days 
there resulted 6 sets of readings per group of rats. Means ± S.D. of total 
accumulated counts were calculated at each hour interval. On a given day 
incremental counts per 30 minutes were determined simply by subtracting a 
given reading from the next reading . Means ± S.D . of these values were calcu-
lated for each half-hour interval. The results of a typical study are given 
in Table 14 and 15 and Figures 7 and 8. 
In Table 14 the means ± S.D. of the incremental counts per 30 minutes 
for 6 hours are tabulated for each of the 2 groups of rats. The C values are 
also presented and these data are graphed in Figure 7. It is quite obvious 
that at 30 minutes mean counts are highest and C values are lowest. As the 
time increases , mean values drop and C values increase greatly. 
A comparison, at each given time level, of the results of group 1 
against the results of group 2 showed that only at the 5!-6 hour interval was 
there a significant change between the two untreated groups. At first glance 
it would appear, then, that since there were no differences between the 2 
groups of rats except for the last 30-minute interval, any interval or all of 
the intervals may be used in studying the effects of drugs on locomotor acti-
vity. It is postulated, however, that this should not be done. 
As the C value increases the randomness of values about a mean increases. 
For example, in Table 14, group 1, the reading at the half-hour level is 
1241 ! 296 , C = 243. In this interval the range of the 6 counts was 1099-1812 
as determined from the raw data. At the 2- hour interval the reading is 7 ! 10, 
C = 1403: that is, in the 30 minutes between l! hours and 2 hours the same 
rats registered, on 6 alternate days, counts ranging from 0 to 25. An 
inspection of the data generated by group 2 in the same cage at the same 
time intervals shows that the results are similar to group l; the C value 
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in the first half-hour interval is 223 and at the 2-hour point is 1563. 
Since at neither time interval was a comparison of group 1 against group 2 
significant at the 0.05 level it would appear only of academic interest to 
use the interval with the lowest C value. But in measuring the effects of 
drugs on locomotor activity in rats one wants first to determine the ability 
of the method to detect a difference between the control group and the drug-
treated group if a difference exists. How efficient, then, is the 2-hour 
reading in detecting a difference, at the 0.05 level, between 2 groups of 
rats as compared to the efficiency of the half-hour reading? A higher C value 
implies greater randomness and therefore reduced efficiency. Snedecor (1956) 
has indicated, however, that the following formula may be used to more exactly 
specify the efficiency of the experiment: 
S .D. t 
delta = ~~_...;0~5-
VN 
S.D. is the standard deviation, N is the sample size, t is the t-value at the 
0.05 level of significance and delta is the smallest difference in the mean 
that the experiment will detect. Using values from group 1 of Table 14 and 
the t-value indicated in the table of t-distribution (Snedecor, 1956) for 
5 degrees of freedom at the 0.05 level, delta at the first 30-minute interval 
is 310. The mean is 1241; 310/1241 x 1003 = 253. Thus, at the first half-hour 
interval the smallest increase or decrease in activity that the method will 
detect is 253 of the mean. By contrast, at 2 hours one must wait for a change 
of 1573 in the mean before a significant difference at the 0.05 level can be 
obtained. 
Similar calculations carried out on the data from the other time-
intervals indicated that experimental efficiency decreases as C values in-
crease. Thus it is clear that only the first 30-minute reading need be 
considered in these studies. 
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In Table 15 and Figure 8 a similar presentation of total cumulative 
counts per hour from the same cage is seen. Both these data and the data pre-
sented above and in Tables 14 and Figure 7 were derived, of course, from the 
same set of raw data. In the total cumulative counts the C values at one hour 
are higher than the 30-minute count but lower than the C value of the 30-60 
minute interval. The means ! S.D. of all C values from all 4 cages are plotted 
in Figure 9. It is obvious that the C values are lowest at the first 30-minute 
interval. Since maximum efficiency is desired, the use of only the first 30-
minute interval is indicated. 
This preliminary study was run for 22 days; each group of 3 rats spent 
11 alternate days in the cage. Use of 4 cages required 24 animals. It was 
surprising, in analyzing the 22-day data, to find incidences of significant 
differences between 2 groups of untreated animals, both in the incremental 
counts per 30 minutes and in the total cumulative counts. These incidences are 
tabulated in Tables 16 and 17. After it was noted that two of these differ-
ences occurred at the first 30-minute interval (Table 16) where experimental 
efficiency is highest, it occurred to the investigator that perhaps similar 
animals do not always behave similarly. But it was recalled that near the end 
of the 22-day period the rats were observed to be jumping up to the grids at 
the top of the actophotometers. Consequently, different portions of the 22-day 
study were separately analyzed in order to determine if there was in fact in-
creased randomness near the end of the study. Tables 16 and 17 show that most 
of the significant differences of the 22-day data disappeared when only the 
first 12 days were analyzed. Moreover, differences in the last 2 weeks of the 
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study, days 9-22 , were much higher than in the first 12 days . Thus it may be 
postulated that after many exposures to the actophotometer rats adapted at 
different rates, revealing differences between groups. This is analogous to 
training rats for psychological studies: some always learn a given lesson 
faster than others . It is recommended, then, to use no more than 6 or 7 runs 
in the cage per group, if the added effect of varying degrees of adaptation to 
the cages would be avoided. 
The one incidence of significant difference between two untreated groups 
of rats, appearing at the first 30- minute interval in cage III, must be accepted 
as evidence that similar animals do on occasion behave differently (Table 16). 
It is because of findings such as this that statistical analysis, indicating 
the degree of confidence to be placed in the reported results, must accompany 
any study of this nature. 
Gylys (1964) reported that modaline HCl, a MAO inhibitor, induced in-
creased locomotor activity in mice, as measured by total counts, after 5 hours 
in the actophotometer. For this reason the 6-hour activity period was used 
in the present work, even though the preliminary study showed that a single 
count at 30 minutes was more efficient than total counts over a period of 5 or 
6 hours. Moreover , a 6-hour run with drugs afforded a check on the method. 
In studies using actophotometer cages for analysis of locomotor activity 
a "warmup" or equilibration period is often used . A " warmup" is simply a delay 
of about 5 to 30 minutes between the time that animals are placed in the cage 
and the time that the counters are turned on. Watzman et al. (1964) indicated 
that such delays increase experimental error. This effect can readily be shown 
in the present work. Using the data in Table 14 it has been shown that the 
30-minute count in group 1 has a C value of 243. The delta or efficiency value, 
calculated using Snedecor's formula as indicated above , is 253 : that is, a 
change of 253 in the mean values is the smallest that can be detected at the 
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0.05 level. Now if a "warmup" of 30 minutes had been employed the incremental 
count from 30- 60 minutes wou ld have been t he first reading obtained. At this 
interval (1 hour) the C value is 633 and the smallest significant detectable 
change from mean values is 663. 
Thus the use of a "warmup" period results only in decreased efficiency. 
In the work of Veldcamp ~al. (1965) the C value was approximately 503. 
These investigators used a "warmup" period of 10 minutes before turning on the 
counters for a 30- minute count. 
It is the opinion of the investigator that the increase in C values and 
the accompanying decrease in efficiency seen after the first 30-minute interval 
can be accounted for by a gradual decrease in the exploratory activity of rats. 
It was repeatedly observed that when rats are placed in an unfamiliar environ-
ment they immediately explore it fully. This results . of course. in increased 
bodily activity . But after 30-45 minutes exploratory activity wanes, and after 
several hours the rats exhibit a pattern sure ly familiar to all workers housing 
these animals in cages : very little movement and a tendency to gather together 
in one area of the cage. After one hour in the actophotometers the rats ex-
hibited this pattern . 
These obse rvations prompted the investigator to conclude that the high 
efficiency of the first 30-minute count in the actophotometer resulted because 
exploratory activity in the cage is more constant than normal rat activity in 
familiar surroundings. In using only one count after 30 minutes to test the 
effects of drugs it must be kept in mind that one is measuring the effects of 
drugs on exploratory activity and not on normal cage activity. It is probably 
not rash to conclude that with the actophotometers currently in use the measure-
ment of normal cage activity is of lit tle or no value in the screening of drugs. 
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F. Activity Studies : The Effects of Thyroxine~ Pargyline. 
The effects of daily treatment for 11 days with thyroxine, pargyline 
and combined thyroxine and pargyline on the locomotor activity of rats are 
given in Tables 18 to 25 and summarized in Tables 26 and 27. 
In Tables 18 and 22 it is shown that there were no differences in the 
locomotor activity of two groups of rats treated with vehicle (glass-distilled 
water) . 
The effects of thyroxine on locomotor activity are seen in Tables 19 
and 23. Thyroxine-treated animals showed a significant depression of activity 
at the first 30-minute level (Table 19). Significant increases in activity at 
the 2-hour and the 2~-hour intervals are not considered meaningful in view of 
what has been shown above concerning the efficiency of the method past the 30-
minute interval. Total cumulative counts (Table 23) in the thyroxine-treated 
group were also significantly less than control values in the 1-4 hour period. 
Close scrutiny of the data shows, however, that the decrease occurred in the 
first hour only; after one hour activity in both groups was similar. 
Pargyline treatment (Tables 20 and 21) elicited a decrease in activity 
at the 30-minute level (Table 20). Again, the single increase at 2 hours is 
not considered meaningful. Total cumulative counts in the pargyline-treated 
group of rats were depressed only at the 1-hour level (Table 24), again re-
flecting a carryover of the depression seen in the first 30 minutes. 
Treatment with both thyroxine and pargyline (Tables 21 and 25) elicited 
depression of activity in the first 30 minutes (Table 21) . The increased acti-
vity at the 2-hour and at the 2!- hour intervals is not considered meaningful. 
There was no significant change in cumulative counts (Table 25). 
Tables 26 and 27 were drawn up from the data of the preceding 8 tables; 
all instances of significant changes elicited by drug treatment are summarized 
here for convenience. It is obvious that 11 days of treatment with thyroxine, 
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pargyline and both drugs in combinat i on elicited over this period a decrease 
in exploratory cage activity in rats as measured in the first 30-minute in-
terval (Table 26). In the rats receiving thyroxine alone or pargyline alone 
this depression was severe enough to affect the 1-hour cumulative count 
(Table 27) and in the thyroxine-treated rats the depression in the first half-
hour was severe enough to show depression of total incremental counts for the 
next 3 hours. It should be emphasized again that this 4-hour decrease does 
not reflect actual depression of activity for 4 hours but only severe depres-
sion in the first 30 minutes. This finding tends to support the view of the 
investigator that in rats only exploratory activity can be consistently 
measured. 
That thyroxine should depress rat exploratory activity is not surprising . 
The metabolic and clinical effects of hyperthyroidism have already been dis-
cussed; in view of the protein-reducing effects in skeletal muscle alone one 
might expect decreased activity. 
The questionable status of pargyline as a psychic energizer has already 
been discussed in the literature survey. The finding in the present study 
that pargyline depresses exploratory activity in rats may possibly be in agree-
ment with the work of Barsa and Saunders (1964) who found frequent increases 
in psychotic symptoms when MAO inhibitors alone were given to depressed patient s . 
It is certainly not in agreement with the report of Kline (1961), who felt that 
MAO inhibitors were quite effective in lessening the symptoms of such patients. 
It is difficult to correlate these psychiatric findings and it is even more 
difficult to extrapolate to depressed patients the results of work with normal 
rats. In 1961, however, Kline did not have the accumulated clinical experience 
with MAO inhibitors that was available in 1964 to investigators suoh as Barsa 
and Saunders. Thus it is possible that the recent extensive psychiatric studie s 
with MAO inhibitors and increased familiarity with their effects may result in 
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some revision of older views concerning the psychiatric efficacy of these 
drugs when used without supportive drug therapy. It is possible that the 
enigmatic increased apathy seen by Kline in psychotic patients receiving both 
MAO inhibitors and thyroid may have been a manifestation of the reported in-
creases in psychotic symptoms seen after MAO inhibitor therapy alone. ' At any 
rate the depressed exploratory activity seen in the present study in rats 
receiving both thyroxine and pargyline is not at all enigmatic after it is 
observed that each drug separately also caused a similar depression. 
G. Correlations 
Depression of exploratory activity in rats receiving thyroxine or both 
thyroxine and pargyline was accompanied by significant weight loss in both 
groups. Depression was accompanied by increased sodium and potassium excre-
tion and sustained hypertension in the thyroxine-treated animals; in the gcoups 
receiving pargyline or both thyroxine and pargyline depression was accompanied 
by total suppression of terminal MAO activity in brain and liver. 
Thus any one of the several effects induced by thyroxine treatment can 
be accompanied by depression . Moreover, depression can be accompanied by total 
suppression of MAO activity in brain and liver . No one effect, however, ac-
companied depression in all three experimental groups, and thus it is concluded 
that depression of exploratory activity in rats can be accompanied by a variety 
of physiological changes. 
VI. SUMMARY AND CONCLUSIONS 
A. The effects of chronic treatment with thyroxine, pargyline and combined 
thyroxine and pargyline were studied on locomotor activity, systolic blood 
pressure, urinary sodium and potassium excretion, body weight gains and ter-
minal monoamine oxidase activity in brain and liver of male albino rats. 
B. A revised actophotometric method for measuring the effects of chronic 
drug treatment on the locomotor activity of rats was established. A single 
reading at 30 minutes was the most suitable measure of exploratory activity, 
since comparisons of 30-minute readings provided the most sensitive and re-
producible index for measuring drug responses on activity. Readings beyond 
the 30-minute interval exhibited greatly reduced sensitivity in detecting drug-
induced changes in locomotor activity. It appears that this actophotometric 
method for measuring the exploratory activity of rats during chronic drug 
treatment has not been previously described. 
C. Analyses of body weights recorded in these studies indicated that compari-
sons of cumulative weight gains from day 0 of drug treatment provided the most 
sensitive and reproducible index for determining changes induced in body weights 
by various factors . 
D. Daily administration of thyroxine induced a sustained hypertension and a 
suppression of cumulative weight gains, both commencing on day 2 and lasting 
for at least 17 further days of treatment. Thyroxine treatment induced signi-
ficant increases in urinary sodium ~nd potassium excretion beginning on day 6 , 
and over 11 days of treatment thyroxine induced a depression in exploratory 
activity. Terminal MAO activity in brain and liver was not affected. 
E . Pargyline administered daily induced sustained hypotension beginning be-
tween days 2 and 7 of treatment and lasting for at least 17 further days of 
treatment. No weight loss or changes in urinary sodium or potassium excretion 
were seen. Pargyline induced a depression in exploratory activity over the 
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11 days of treatment and completely suppressed monoamine oxidase activity in 
brain and liver after 11 days of treatment or longer. 
F. Concurrent administration of both thyroxine and pargyline did not induce 
changes in blood pressure after 3 days of treatment . Cumulative weight gains 
were continually suppressed from day 1 . Urinary sodium and potassium excre-
tion was not significantly altered, but depression of exploratory activity 
over the 11 days of treatment was induced, and terminal monoamine oxidase 
activity in brain and liver was completely suppressed. 
G. Qualitative observations indicated that thyroxine increased the heart rate 
and stroke volume . This effect was not abolished when pargyline was given 
together with thyroxine, but pargyline alone appeared to reduce heart rate and 
stroke volume. 
H. The implications of these findings are discussed. 
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